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Pacemakers, implantable cardiac defibrillators, and cardiac resynchronization therapy devices are potentially life-saving treatments for a
number of cardiac conditions, but are not without risk. Most concerning is the risk of a cardiac implantable electronic device (CIED) infec-
tion, which is associated with significant morbidity, increased hospitalizations, reduced survival, and increased healthcare costs.
Recommended preventive strategies such as administration of intravenous antibiotics before implantation are well recognized.
Uncertainties have remained about the role of various preventive, diagnostic, and treatment measures such as skin antiseptics, pocket anti-
biotic solutions, anti-bacterial envelopes, prolonged antibiotics post-implantation, and others. Guidance on whether to use novel device
alternatives expected to be less prone to infections and novel oral anticoagulants is also limited, as are definitions on minimum quality
requirements for centres and operators and volumes. Moreover, an international consensus document on management of CIED infections
is lacking. The recognition of these issues, the dissemination of results from important randomized trials focusing on prevention of CIED
infections, and observed divergences in managing device-related infections as found in an European Heart Rhythm Association worldwide
survey, provided a strong incentive for a 2019 International State-of-the-art Consensus document on risk assessment, prevention, diagno-
sis, and treatment of CIED infections.
...................................................................................................................................................................................................
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Introduction
Scope of the consensus document
Pacemakers (PM), implantable cardiac defibrillators (ICDs), and
cardiac resynchronization therapy (CRT) devices are life-saving
treatments for a number of cardiac conditions. Device-related in-
fection is, however one of the most serious complications of car-
diac implantable electronic device (CIED) therapy associated
with significant morbidity, mortality, and financial healthcare bur-
den. Although many preventive strategies such as administration
of intravenous (i.v.) antibiotic therapy before implantation are
well recognized, uncertainties still exist about other regimens.
Questions still remain such as the use of CIED alternatives
expected to be less prone to infections and how to manage medi-
cation, such as anticoagulants during CIED surgery, and the role
of minimum quality and volume requirements for centres and
operators. The recognition of these gaps in knowledge, reports
of new important randomized trials, observed divergences in
managing device-related infections,1 and the lack of international
consensus documents specifically focusing on CIED infections
provided a strong incentive for a 2019 State-of-the-art
Consensus document on risk assessment, prevention, diagnosis,
and management of CIED infections. The aim of this document is
to describe the current knowledge on the risks for device-related
infections and to assist healthcare professionals in their clinical
decision making regarding its prevention, diagnosis, and manage-
ment by providing the latest update of the most effective
strategies.
Methodology
This consensus document is an international collaboration among
seven professional societies/associations, including the European
Heart Rhythm Association (EHRA), the Heart Rhythm Society
(HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin
American Heart Rhythm Society (LAHRS), the European Association
for Cardio-Thoracic Surgery (EACTS), the European Society of
Clinical Microbiology and Infectious Diseases (ESCMID), and the
International Society for Cardiovascular Infectious Diseases
(ISCVID). The writing group consisting of 16 Task Force Members,
were selected based on their expertise and medical specialty (12 car-
diologists with varying subspecialties, 2 infectious disease specialists, 1
imaging specialist, and 1 thoracic surgeon), from 11 countries in 4
continents.
All experts undertook a detailed comprehensive literature search
until May 2019 (human research published in English and indexed in
major databases such as MEDLINE, EMBASE, the Cochrane Library,
and others as required) related to studied patient cohort and CIED
infection topics using relevant search terms related to the field and
prior guidelines. Systematic reviews of published evidence for
management of given conditions and clinical problems were per-
formed. Members were asked to weigh the strength of evidence for
or against a particular diagnostic instrument, procedure, or treat-
ment, include estimates of expected health outcomes and assess
risk–benefit ratios where data existed. Patient-, device-, and
procedure-specific modifiers were considered, as were the results of
the international survey on CIED infections conducted for this pur-
pose1 and of previous registries.2 Consensus statements were
evidence-based, derived primarily from published data and by con-
sensus opinion after thorough deliberations, requiring at least 80%
predefined consensus delivered via email by chairs to all expert mem-
bers for their approval/rejection.
The EHRA user-friendly ranking system, for consensus documents,
with ‘coloured hearts’ providing the current status of the evidence
and consequent guidance was used for the coding of the scientific evi-
dence for statements made (Table 1). The grading does not have sep-
arate levels of evidence, which instead are defined in each of the
coloured heart grades. A letter coding ‘ROME’ defining existing scien-
tific evidence was applied: R for randomized trials, O for observa-
tional studies, M for meta-analyses, and E for expert opinion
(Table 1).
The document was peer-reviewed by official external reviewers
representing EHRA, the participating societies, and ESC Committee
for Practice Guidelines (CPG). All members of the writing group as
well as reviewers have disclosed potential conflicts of interest, at the
end of this document.
Since this consensus document includes evidence and expert opin-
ions from various countries and healthcare systems, the medical
approaches discussed may include drugs or devices that are not ap-
proved by governmental regulatory agencies in all countries.
Moreover, the ultimate decision on management must be made by
the healthcare provider and the patient in light of individual factors
presented.
Background and epidemiology
Over the last decades, there has been a substantial increase in the
number and complexity of CIED implantations as a result of ex-
panded indications and progressive aging of the population. Although
these devices improve cardiovascular outcomes, they also expose
patients to a risk for potential complications.
Infection is one of the most serious complications of CIED therapy
and is associated with significant mortality, morbidity, and financial
healthcare burden. It is difficult to give a precise rate of CIED infec-
tions because of divergent definitions, varied populations, and the
range of rates in retrospective and prospective studies. In the Danish
registry including 46 299 consecutive patients who underwent pace-
maker implantation between 1982 and 2007, the incidence of infec-
tion was 4.82/1000 device-years after a primary implantation, and
12.12/1000 device-years after replacement.3 Greenspon et al. found
that the incidence of CIED infection in the USA increased from
1.53% in 2004 to 2.41% in 20084 and a National Inpatient Sample
database study showed an increase from 1.45% to 3.41% (P< 0.001)
from 2000 through 2012, particularly for CRT devices.5 Infection
rates in prospective observational studies,6,7 registries8 and more
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recent cross-over cluster PADIT- and randomized WRAP-IT tri-
als,9,10 were only 0.6–1.3%, as compared to retrospective studies,11,12
reporting significantly higher rates (2.3–3.4%) in the first year after
implantation.
Pathogenesis and microbiology of
cardiac implantable electronic
device infections
Cardiac implantable electronic device infections occur via two major
mechanisms. The most common is contamination of leads and/or
pulse generator during implantation or subsequent manipulation.13
Device erosion late after interventions may either be due to, or result
in pocket infection. In either case, contamination and subsequent bac-
terial colonization result in pocket infection which can spread along
the intravascular parts of the leads and progress to systemic infection.
The second mechanism is a bloodstream infection.14 Direct lead
seeding can occur during bacteraemia caused by a distant infectious
focus, such as a local septic thrombophlebitis, osteomyelitis, pneumo-
nia, surgical site infection, contaminated vascular catheters or bacte-
rial entry via the skin, mouth, gastrointestinal, or urinary tract.
Factors, which play a role in the pathogenesis of CIED infections,
can be related to the host, the device, or the microorganism. The
patient’s own skin flora can be introduced into the wound at the time
of skin incision and thereby contaminate the device. Contamination
may also occur before implantation via the air in the operating room
(both host and staff) or via the hands of anyone handling the device.
From a pathophysiological standpoint, device-related factors are
those affecting bacterial adherence to the generator or lead and the
biofilm formation on these surfaces. Bacterial adherence is facilitated
by irregular and hydrophobic surfaces.15 Of the commonly used poly-
mers, polyvinylchloride and silicone allow better adherence than pol-
ytetrafluoroethylene, while polyurethane allows less adherence than
polyethylene. Metals also differ in their propensity for bacterial ad-
herence—e.g. titanium has less propensity for bacterial adherence
than steel. Normally non-pathogenic microorganisms such as
Coagulase-negative Staphylococci (CoNS) may adhere to the CIED
and establish a focus of infection. The microorganisms most fre-
quently isolated have been Gram-positive bacteria (70–90%), espe-
cially CoNS (37.6% of the isolates) and Staphylococcus (S.) aureus
(30.8%), which are far more prone to adhere to non-biological mate-
rial than others (Table 2).16,17,19 Staphylococcus aureus is the most
common cause of bacteraemia and early pocket infections.
Altogether, methicillin-resistant staphylococci were isolated in 33.8%
of CIED infections (49.4% of all staphylococcal infections),16 their fre-
quency varied by country, and even hospital.18,20 Over the past de-
cade the rates of methicillin resistance seem to be greater than those
reported earlier.16 Gram-negative bacteria were isolated in 8.9%
while other microbes such as streptococci, anaerobes, and fungi
were less often isolated (Table 2). Enterobacteriaceae, other Gram-
negative rods and fungi were rare (Table 2).
Risk factors for cardiac
implantable electronic device
infection
Risk factors for CIED infection may be divided into patient-related,
procedure-related, and device-related factors. These risk factors may
....................................................................................................................................................................................................................
Table 1 Scientific rationale of recommendations
Consensus statement
related to a treatment
or procedure
Definitions of consensus statement Statement class Scientific evi-
dence coding
(SEC)
Ref.
Recommended/indicated or
‘should do this’
Scientific evidence that a treatment or proce-
dure is beneficial and effective. Requires at
least one randomized trial, or is supported by
large observational studies and authors’
consensus
R
May be used or
recommended
General agreement and/or scientific evidence fa-
vour the usefulness/efficacy of a treatment or
procedure. May be supported by randomized
trials based on small number of patients or
not widely applicable
O
Should NOT be used or
recommended
Scientific evidence or general agreement not to
use or recommend a treatment or procedure
E
This categorization for the consensus document should not be considered as being directly similar to that used for official society guideline recommendations which apply a
classification (I–III) and level of evidence (A, B, and C) to recommendations.
The ‘ROME’ coding was applied for each consensus statement, defining existing scientific evidence.
E, expert opinion; M, meta-analyses; O, observational studies; R, randomized trials.
516b C. Blomstro¨m-Lundqvist et al.
be modifiable or non-modifiable. Identification of modifiable risk fac-
tors is important because they may allow for preventive measures to
reduce the risk. In patients with non-modifiable risks, alternative
approaches may be an option to lower the overall risk. For example,
renal dialysis is a non-modifiable patient risk factor. By changing the
procedure and/or device and selecting an epicardial or subcutaneous
system the risk may be reduced. Several studies have examined large
databases for the most common risk factors. A meta-analysis21 of
pooled data including 206 176 patients in 60 studies (of which 21
were prospective and 39 retrospective) is presented in Table 3.
Other large studies analysing risk factors include device registry data
matched with Medicare fee-for-service claims data,22 the National
Inpatient Sample database study with 85 203 device-related infec-
tions,5 and the recent Danish device-cohort study, including 97 750
patients.23
A summary of the most important risk factors identified in these tri-
als are listed in Table 3 (adapted from Polyzos et al.21) Unfortunately,
the importance of risk factors varied from study to study and in some
cases findings were contradictory (age as an example).
Of the patient-related factors, end-stage renal disease was consis-
tently associated with the highest risk, underscoring the importance
of a careful clinical evaluation in these patients. In the meta-analysis
risk factors included: end-stage renal disease, renal insufficiency, dia-
betes mellitus, chronic obstructive pulmonary disease, corticosteroid
use, history of previous device infection, malignancy, heart failure,
pre-procedural fever, anticoagulant drug use, and skin disorders, but
not age or gender.21 However younger age, along with prior device
infection were identified as significant risks in the Danish device-
cohort study.23 Others identified malnutrition (OR 2.44, P< 0.001)
as a strong risk factor.5
Regarding procedure-related factors, antibiotic prophylaxis was as-
sociated with a 70% relative risk reduction in infection and is now the
standard of care.21 The presence of a haematoma was associated
with an approximately nine-fold increased risk of infection. These
findings were later confirmed by the prospective BRUISE-
CONTROL study, which reported data from 659 patients in whom
there was a hazard ratio of infection of 7.7 (95% CI 2.9–20.5;
P< 0.0001) in case of clinically significant haematoma (requiring sur-
gery and/or resulting in prolonged hospitalization >_24 h, and/or re-
quiring interruption of anticoagulation), with as many as 11% of these
patients developing this complication over 1-year follow-up.24 Early
reoperation for haematoma or lead dislodgement were identified as
the strongest risk factors for CIED infection in a device registry data
matched with Medicare fee-for-service claims data.22 Haematoma
was also one of the strongest risk factors (OR 2.66, P< 0.001) in a
National Inpatient Sample database study.5 Procedure duration was
associated with a multifold increased risk of infection, although there
was significant heterogeneity in the studies.21 Data from the Danish
device registry23 showed that compared to procedures lasting <30
min, the relative risk [95% CI] of infection for procedures lasting 60–
90, 90–120, or >120 min were 1.54 [1.24–1.91], 1.85 [1.36–2.49],
and 2.42 [1.77–3.33], respectively. The same registry identified im-
plantation of CRT and reoperations as high and significant risks.23
Another study confirmed early lead repositioning as a strong predic-
tor of infection although it is as yet unknown whether delaying the
re-intervention would reduce risk.21 Temporary pacing has also been
...............................................................................................................
....................................................................................................................................................................................................................
Table 2 Pathogens isolated in patients undergoing interventions for device infection from three large patient cohorts
in North America, Europe, and Asia
Percentage of isolates
Pathogen North America16 Europe17 Asia18
Coagulase-negative staphylococci 69 45.2
Methicillin-resistant 18.8
Methicillin-sensitive 18.8
S. aureus 13.8 4.1
Methicillin-sensitive 15.8
Methicillin-resistant 15.0
Streptococcus spp. 2.5
Enterococcus spp.
Vancomycin-sensitive 2.8
Vancomycin-resistant 1.4
Cutibacterium spp. (previously Propionibacterium spp.) 2.5
Corynebacterium 5
Gram-negative bacteria 8.9 6.1 9.1
Enterobacteriaceae 3 3.2
Non-fermentative bacilli, incl. Pseudomonas spp. 1.5 5.9
Anaerobes 1.6
Fungi 0.9 1 0.9
Mycobacteria 0.2
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shown to increase the risk of infection21 (and carries a risk of perfora-
tion/tamponade). This may be due to deviations in sterility measures
due to urgent placement, need for lead re-manipulation and simply as
a chronic portal of entry to the bloodstream. Indication for tempo-
rary transvenous pacing should therefore be carefully considered,
and alternative measures such as backup transthoracic pacing or infu-
sion of rate-accelerating drugs evaluated. Device generator replace-
ment roughly doubles the risk of infection, possibly due to activation
of pre-existing bacterial colonization or reduced penetration of anti-
biotics into the encapsulated generator pocket.21 As with any proce-
dure, experience has an impact on outcome,25 and risk of infection
may be increased by allocating generator changes to inexperienced
operators.
There are fewer device-related factors for CIED infection. After
restricting analysis to prospective studies, an abdominal pocket was
the only significant risk factor,21 although factors such as patient pro-
file and type of intervention may have confounded the results. Data
from the Danish registry23 showed that device complexity and the
numbers of leads were factors significantly associated with increased
infection risk on multivariate analysis with a HR of 1.26, 1.67, and 2.22
for ICD, CRT-P, and CRT-D systems, respectively as compared to
PMs (P<_ 0.002 for all comparisons).
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Table 3 Pooled effect estimates for potential risk factors predisposing to cardiac implantable electronic device
infection
Prospective1 retrospective studies Prospective studies only
Factor Studies
(n)
Total
(n)
Pooled
estimate
P-value Studies
(n)
Total
(n)
Pooled
estimate
P-value
Patient-related factors
ESRDa 8 3045 8.73 [3.42, 22.31] 0.00001 NA
History of device infection 4 463 7.84 [1.94, 31.60] 0.004 NA
Fever prior to implantation 3 6652 4.27 [1.13, 16.12] 0.03 2 6580 5.34 [1.002, 28.43] 0.05
Corticosteroid use 10 3432 3.44 [1.62, 7.32] 0.001 3 1349 2.10 [0.47, 9.32] 0.33
Renal insufficiencyb 5 2033 3.02 [1.38, 6.64] 0.006 NA
COPD 6 2810 2.95 [1.78, 4.90] 0.00003 2 2393 2.30 [0.97, 5.48] 0.06
NYHA class >_ 2 3 2447 2.47 [1.24, 4.91] 0.01 2 2393 2.77 [1.26, 6.05] 0.01
Skin disorders 4 6810 2.46 [1.04, 5.80] 0.04 2 6519 2.60 [0.88, 7.70] 0.08
Malignancy 6 1555 2.23 [1.26, 3.95] 0.006 NA
Diabetes mellitus 18 11839 2.08 [1.62, 2.67] <0.000001 7 9815 1.88 [1.19, 2.98] 0.007
Heparin bridging 2 6373 1.87 [1.03, 3.41] 0.04 NA
CHF 6 1277 1.65 [1.14, 2.39] 0.008 NA
Oral anticoagulants 9 8527 1.59 [1.01, 2.48] 0.04 3 7271 1.18 [0.44, 3.11] 0.75
Procedure-related factors
Procedure duration 9 4850 9.89 [0.52, 19.25] 0.04 6 4508 13.04 [-0.64, 26.73] 0.06
Haematoma 12 14228 8.46 [4.01, 17.86] <0.000001 6 9715 9.33 [2.84, 30.69] 0.0002
Lead repositioning 5 1755 6.37 [2.93, 13.82] 0.000003 4 1659 7.03 [2.49, 19.85] 0.0002
Inexperienced operatorc 2 1715 2.85 [1.23, 6.58] 0.01 2 1715 2.85 [1.23, 6.58] 0.01
Temporary pacing 10 10683 2.31 [1.36, 3.92] 0.002 4 8683 3.29 [1.87, 5.80] 0.00004
Device replacement/revision/upgrade 26 21214 1.98 [1.46, 2.70] 0.00001 8 8793 0.95 [0.49, 1.87] 0.89
Generator change 20 12134 1.74 [1.22, 2.49] 0.002 6 2139 0.91 [0.37, 2.22] 0.83
Antibiotic prophylaxis 16 14166 0.32 [0.18, 0.55]d 0.00005 11 10864 0.29 [0.13, 0.63] 0.002
Device-related factors
Epicardial leads 3 623 8.09 [3.46, 18.92] 0.000001 NA
Abdominal pocket 7 4017 4.01 [2.48, 6.49] <0.000001 2 2268 5.03 [1.96, 12.91] 0.0008
>_2 leads 6 1146 2.02 [1.11, 3.69] 0.02 NA
Dual-chamber device 14 45224 1.45 [1.02, 2.05] 0.04 7 12102 1.28 [0.73, 2.25] 0.38
Risk parameters which were statistically significant for retrospective and prospective data are shown. Analyses restricted to prospective data only for the same parameters (if
available) are also shown. Adapted from Polyzos et al.21
CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; NA, not available; NYHA, New York Heart Association.
aGFR <_15 mL/min or haemodialysis or peritoneal dialysis.
bGlomerular filtration rate (GFR) <60 mL/min or creatinine clearance (CrCL) <60 mL/min.
c<100 previous procedures.
dThe pooled effect estimate from randomized studies was 0.26 [0.13, 0.52].
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Risk stratification
Considering that CIED infections occur in the presence of multiple
host and procedure-related factors, risk scores have been developed
to identify patients at low and high risk. Scoring systems could play a
role in better identifying patients at risk than individual factors, espe-
cially considering the inconsistency of the reported factors in various
studies.
A single centre study of 2891 ICD or CRT-D recipients identified a
novel composite score of 7 independent risk factors for infection and
defined patients as low (1% risk), medium (3.4%), and high (11.1%)
risk for infection.26 Related to its moderate predictive range, the
model has not been adopted for risk stratification. Another study
identified 10 preoperative risk factors associated with CIED infection
for a risk score system that defined score <1 as low risk (1%) and >_3
as high risk (infection rate 2.4%).27 Despite the potential practical use
of such risk scores, they can currently not be recommended because
the evidence behind them remains weak.
Prevention
A summary of recommended preventive measures is shown in
Table 4. A flowchart that indicates how modifiable risk factors can be
minimized on various levels is shown in Figure 1.
Pre-procedural measures
Patient selection
The best treatment of device-related infections is prevention.
Careful consideration should be given to whether the risks of de-
vice implantation, in any individual patient, outweighs the benefit. If
there is a significant risk of infection delay of implantation for a pe-
riod of observation or longer-term antibiotic treatment might be
of value. For patients undergoing device removal for infection,
one-third to one-half may not require device re-implantation.38 If
the decision is to proceed with an implantation, it is important to
‘think before you choose’. Avoiding a transvenous system, and
implanting an epicardial system, may be preferential in high-risk
patients.39 There is hope that ‘leadless’ pacemakers will be less
prone to infection and can be used in a similar manner in high-risk
patients.40,41 Subcutaneous ICDs (S-ICD) are an option in patients
requiring sudden death protection without requiring pacing.
Decisions must be made on an individual basis, weighing all known
risks and benefits.
Lead management
The number of leads and the presence of abandoned leads are associ-
ated with increased risk for complications, including infection. The
decision to abandon or extract a lead can be complex and must be
made on an individual basis weighing all known risks and benefits. The
increased risk of infection, and increased risk of extraction if an infec-
tion occurs, must be considered in this decision.42,43
Patient factors
In patients who have fever or signs of active infection, a procedure
should be delayed until a patient has been afebrile for at least 24 h.28
The need for temporary pacing wires increases the risk of infection
and should be avoided if possible.28 Temporary pacing via a jugular
route may provide a lower risk of infection than groin access, al-
though this remains to be proven. Studies have demonstrated that
better glycaemic control in the peri-procedural period may reduce
infections in surgical patients.44
Anticoagulation and antiplatelet drugs
The development of a pocket haematoma increases the risk for in-
fection.24 Studies have demonstrated that a ‘bridging’ approach
with anticoagulation increases the risk of haematoma and is no lon-
ger recommended.30 In patients who are not at high risk for
thrombo-embolic events (e.g. CHA2DS2VASc score <4), holding
anticoagulation for the procedure and restarting when the bleed-
ing risk is reduced seems prudent. In higher-risk patients, such as
those with prior embolic event or mechanical valve, continuing
anticoagulation with Warfarin is recommended. Preliminary data
from the BRUISE-Control 2 study suggests the same may be true
for non-vitamin K antagonist oral anticoagulants.29 Therapeutic
low-molecular-weight-heparin (LMWH) should be avoided.30,32,33
Antiplatelet agents, especially P2Y12 inhibitors (clopidogrel, prasu-
grel, ticagrelor) significantly increase the risk for bleeding and
should (unless clearly indicated) preferably be discontinued for 5–
10 days before the intervention, especially if they are combined
with oral anticoagulation.31
Appropriate environment
Both in operating rooms and Electrophysiology/Catheterization labo-
ratories, the standards for sterile procedures (e.g. cleaning, room de-
sign, ventilation, limitation of area traffic, etc.) must be met as for
other surgical procedures associated with implants. Minimum stand-
ards for the environment for CIED procedures have been pub-
lished.41 It is recommended that each centre set up a continuous
surveillance program of their infection rates and flora involved. Data
must be correlated with patient, procedure, staff, and device informa-
tion (Table 4).
Staff training
All staff involved in CIED implantation must be trained in appropriate
strict sterile techniques and behaviour in an operating room setting
(scrubbing, set up of tables, patient preparation, and strict limitation
to room traffic). Operators should be adequately trained45 and
supervised.
Nasal swabs/S. aureus decolonization of patients
For elective procedures, S. aureus colonization can be detected by na-
sal swabs. Nasal treatment with mupirocin and chlorhexidine skin
washing can reduce colonization and has been shown in some surgi-
cal studies to reduce the risk for infection,46 but there are no studies
relating specifically to CIED interventions.
Pre-procedure skin preparation
In many hospitals, pre-surgical washing with an anti-microbial agent is
employed. The data on this practice for general surgical procedures
are diverse and a recommendation for its routine use therefore can
not be strongly supported.47 If chest hair needs to be removed,
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Table 4 List of recommended preventive measures for CIED infections
Consensus statement Statement class Scientific evidence
coding
References
Pre-procedural measures
Confirm indication for CIED E
Delay CIED implantation in patients with infection E 28
Avoid temporary transvenous pacing and central venous lines, which should
ideally be removed prior to introducing new hardware, whenever possible
O, M 21
Measures to avoid pocket haematoma are recommended (avoid heparin bridg-
ing, discontinue antiplatelets if possible)
R 21,29–31
Periprocedural use of therapeutic low-molecular-weight-heparin R, M, O 30,32,33
Perform the CIED procedure in an operating room/suite with complete sterile
environment as required for other surgical implant procedures
E 34
Procedure should be performed or supervised by an operator with sufficient
training and experience (Table 12)
O 45
Topical S. aureus decolonization may be performed E
Pre-procedural skin wash may be performed E
Hair removal with electric clippers (not razors) is recommended O 35
Antibiotic prophylaxis is recommended within 1 h of incision for cefazolin and
flucloxacilline, within 90-120 min for vancomycin
R, M 21
A continuous surveillance program of infection rates and associated microbiol-
ogy should be set-up at the level of each implanting centre
E –
Peri-procedural measures
Surgical preparation with alcoholic chlorhexidine should be used rather than
povidone-iodine
R 36,37
Allow sufficient time for the antiseptic preparation to dry E
Adhesive iodophor-impregnated incise drapes may be used E
Perform the procedure with adequate surgical technique—minimize tissue
damage, haemostasis, adequate wound closure
E
Antibiotic envelope in high-risk situations is recommendeda R 10
If the operator performs the prepping and draping, glove change/re-scrub or
remove outer glove of a double-glove before incision
E
Continued
516f C. Blomstro¨m-Lundqvist et al.
....................................................................................................................................................................................................................
Table 4 Continued
Consensus statement Statement class Scientific evidence
coding
References
Using local instillation of antiseptic and antibiotics in the pocket R, E 9
Use of braided sutures for final skin closure E
Post-procedural measures
Use of postoperative antibiotic therapy R 9
Adequate dressing for 2–10 days is recommended E
Patient instructions on wound care should be provided E
Delay or reconsider indication for re-intervention if possible E
Haematoma drainage or evacuation (unless tense, wound dehiscence is present
or pain is severe)
O 24,28
aCandidates are those as defined in the WRAP-IT study population10 (patients undergoing pocket or lead revision, generator replacement, system upgrade, or an initial CRT-D
implantation) and patients with other high risk factors as outlined in Table 3, considering also the local incidence of CIED infections.
CIED, cardiac implantable electronic device; E, expert opinion; M, meta-analysis; O, observational studies; R, randomized trials.
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Figure 1 A flowchart indicating how device-related infections can be minimized by targeting modifiable risk factors on various levels. Risk factors
ranked in order of strength from top to bottom. CIED, cardiac implantable electronic device; COPD, chronic obstructive pulmonary disease; CRT,
cardiac resynchronization therapy; ICD, implantable cardiac defibrillator; NYHA, New York Heart Association; OAC, oral anticoagulation; w, week.
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electric clippers with a single-use head (and not razors) should be
used on the day of the procedure.35
Pre-procedure antibiotic therapy
The use of prophylactic systemic antibiotics has been proven to
lower infection rates of CIED and is the standard of care.48,49 It signifi-
cantly reduces the incidence of device infection, compared with no
antibiotic therapy, with a 40–95% relative risk reduction.21
Antibiotics must be completed within 1 h of incision to ensure ade-
quate tissue levels. Staphylococcus aureus is the most common organ-
ism involved in acute CIED infections. The degree of methicillin
resistance varies. Antibiotics should at least cover S. aureus species.
Currently, there are no significant data to support routine Methicillin-
Resistant S. Aureus (MRSA) coverage and its usage should be guided
by the prevalence of MRSA in the implanting institution and patient
risk. Randomized trials have used i.v. flucloxacillin (1–2 g) and first-
generation cephalosporins such as cefazolin (1–2 g).9,48,49
Vancomycin (15 mg/kg) may be used in case of allergy to cephalo-
sporins and since it should be administered slowly (approximately
over 1 h) it needs to be started 90-120 min prior to the incision.
Peri-procedural measures
Patient surgical preparation
Randomized studies have demonstrated alcoholic 2% chlorhexidine
to be superior to povidone-iodine (with or without alcohol) for skin
preparation prior to surgery36 or intra-vascular catheter insertion37
but no randomized data exist regarding CIED implantation. The anti-
septic should be allowed to dry completely before incision, in order
to provide sufficient time for it to be effective. In addition, alcoholic
antiseptic agents may carry a fire hazard with electrocautery, espe-
cially if there is pooling. Many operators use adhesive incise drapes,
but there is no evidence that it reduces infection rates (and may even
increase risk of infection when non-iodophor incise drapes are
used50).
Good surgical technique
Minimizing tissue damage, strict attention to haemostasis, and ade-
quate wound closure are all important measures to reduce infection.
Many operators change gloves (e.g. by double-gloving) when draping
the patient and also before handling the generator. Non-powdered
gloves may reduce the risk of infection by reducing local inflamma-
tion.51 Pocket haematoma is associated with an increased risk of in-
fection.24 There are no data supporting the routine use of topical
haemostatic agents, although, they may be useful in selected patients.
Vigorous pocket irrigation is important to remove devitalized tissue
as well as dilute any contaminants.52 Diagnostic or therapeutic aspira-
tion of a haematoma is contraindicated given the risk of ‘inoculating’
the pocket and causing an infection.24,28 Haematoma evacuation
should only be undertaken if pain is unmanageable or wound closure
is threatened, and should ideally be performed in an operating
room.24
Antibiotic envelope
An antibacterial mesh envelope [TYRX
TM
, Medtronic, MN, USA] has
been developed, which locally releases minocycline and rifampin for a
minimum of 7 days to prevent infections and biofilm formation and
is fully absorbed in 9 weeks. The WRAP-IT trial10 has shown that
the envelope significantly reduces the incidence of CIED infection
in high-risk patients (undergoing pocket or lead revision, generator
replacement, system upgrade, or an initial CRT-D implantation)
without a higher incidence of complications. A total of 6983
patients were randomized to receive the envelope or not, with a
lower incidence of primary endpoints (infection resulting in system
extraction or revision, long-term antibiotic therapy, or death)
within 12 months after the CIED implantation in patients who re-
ceived the envelope vs. controls: 0.7% and 1.2%, respectively (haz-
ard ratio 0.60; 95% confidence interval 0.36–0.98; P= 0.04).10
While the population treated showed benefit, the number of
patients needed to treat to prevent one infection was high. The ex-
clusion of higher-risk patients (those treated with immunosuppres-
sive treatments, with vascular access, or on dialysis) may have
contributed to a lower-than-expected rate of infections (1.2%)
also observed in other prospective studies.6,7,9 A heightened
awareness of infection prevention when participating in prospec-
tive trials may also explain such low rates. Higher infection rates
(2.3–3.4%), as observed in less-selected retrospective studies,11,12
would improve the overall cost-effectiveness of the envelope.
Recommendation for the use of the antibacterial envelope is out-
lined in Table 4. The use should be individualized based upon pres-
ence of risk factors (Table 3) and the local incidence of CIED
infections.
The use of other ‘envelopes’ (bioscaffold or pericardium patches)
for stabilization, antibiotic soaked gauze, etc. has not been rigorously
studied and cannot be supported.
Local instillation of antibiotics or antiseptics
While vigorous pocket irrigation is recommended the use of local in-
stallation of an antibiotic or antiseptic is not. The recent PADIT trial
demonstrated no benefit (see below).9
Capsulectomy
Even in the absence of signs of clinical infections, cultures taken at the
time of generator change demonstrate a significant incidence of colo-
nization.53 In addition, the fibrous capsule inhibits the body’s normal
defence mechanisms and antibiotic penetration. Theoretically, ‘capsu-
lectomy’ mitigates these issues but could also result in more pocket
bleeding/haematoma, and therefore cannot be recommended as rou-
tine practice.54
Closure
Wound dehiscence or superficial infection can lead to a frank pocket
infection. Closure in layers minimize wound tension and reduces the
risk of dehiscence and infection.55 Skin closure can be with a subcutic-
ular absorbable suture, non-absorbable suture, surgical staples, or
surgical adhesive. If non-absorbable material is used, it must be
removed in a timely manner when clinically appropriate (usually 7–
14 days). Absorbable sutures must be placed with care to allow for
absorption and avoidance of a ‘stitch abscess’ especially at the site of
the knot. Although there are no data indicating that the type of suture
material impacts the risk of infection, many operators prefer non-
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braided monofilament sutures for skin closure as they may avoid bac-
terial adhesion (see Pathogenesis and microbiology of cardiac im-
plantable electronic device infections section). Some sutures are
impregnated with antibiotics, but since there is no evidence that it
reduces infection, it cannot be recommended over standard sutures.
Post-procedural measures
Post-procedure antibiotic therapy
Some physicians administer post-implant antibiotics from a single
dose to a week i.v. and oral administration.1 The recent PADIT trial,9
with its cluster cross-over design, tested the clinical effectiveness of
incremental perioperative antibiotics to reduce device infection. The
conventional treatment was a single-dose preoperative cefazolin infu-
sion vs. a combination of pre-procedural cefazolin plus vancomycin,
intra-procedural bacitracin pocket wash, and 2-day postoperative
oral cephalexin in almost 20 000 patients undergoing CIED implanta-
tion. The primary outcome of 1-year hospitalization for device
infection in the high-risk group was not statistically significant (non-
significant 20% reduction of infection). The device infection rates
were low. As there are no data supporting this practice, it is not rec-
ommended to administer postoperative antibiotic therapy.
Wound care
An appropriate dressing should cover the incision at the end of the
operation (except in the case of surgical adhesive). Clinical practice
varies with the dressing being left on for 2–10 days. Pressure dressing
may be used for the first 24 h to avoid haematoma. It is not necessary
to change the dressing, unless it becomes impregnated. Some dress-
ings are waterproof and allow the patient to shower. Patients should
be advised to avoid soaking the wound (e.g. by swimming) until it is
entirely healed (which usually takes approximately a month). They
should also be instructed to seek medical attention in case of signs of
local infection.
Re-intervention
It is well known that early re-intervention dramatically increases the
risk of infection,19,21,28 so all measures must be taken to avoid this
need (i.e. avoid haematoma, lead dislodgment, etc.). Some operators
delay re-intervention by weeks (e.g. for lead repositioning) in an at-
tempt to reduce this risk. This strategy may also alleviate the pain as-
sociated with early re-intervention, but further research is needed to
determine whether this effectively reduces the risk of infection.
Diagnosis of cardiac implantable
electronic device infections and
related complications
Clinical findings
A superficial incisional infection should be differentiated from a pocket
infection, as it involves only the skin and the subcutaneous tissue
without communication with the pocket (and hence does not require
CIED system extraction).56,57 Close monitoring of the patient must
be pursued in order to recognize early recurrence that may be a sign
of a significant pocket infection.
Pocket infection is defined as an infection limited to the generator
pocket. It is clinically associated with local signs of inflammation that
may be mild and characterized by erythema, warmth, and fluctua-
tion.14,57 Deformation of the pocket, adherence or threatened ero-
sion are often signs of low grade, indolent infection. Symptoms and
signs of an infected surgical wound may fluctuate and although it can
be difficult to recognize initially it is not recommended to take a sam-
ple of pocket material. Once a wound dehiscence occurs, a purulent
drainage or a sinus is established, and a pocket infection is clearly pre-
sent. If the generator or proximal leads are exposed, the device
should be considered infected, irrespective of the results of the mi-
crobiology. Material from the pocket may be used for culture, recog-
nizing the potential for contamination. Pocket infections may be
associated with lead infections and CIED systemic infections and/or
infective endocarditis. The actual rates depend on the definitions
used in different studies.58
The diagnosis of CIED systemic infection and infective endocarditis with-
out local infection may be more challenging (Table 5). Symptoms may
be non-specific (fever, chills, night sweats) and a long period of time
may elapse between CIED implantation and symptom onset as well
as diagnosis. Patients with CIED infection may present with embolic
involvement of lungs and pleural space, frequently misdiagnosed as
pulmonary infections.61,62 Cardiac implantable electronic device
infections may also be revealed by other distant foci as vertebral os-
teomyelitis and discitis. C-reactive protein (CRP) may be helpful al-
though non-specific and procalcitonin (PCT) test may be of value,
especially if positive (>_0.05) due to the high specificity for pocket in-
fection compared to no infection and in case of embolic phenomena
and S. aureus endocarditis.63,64
There is no standardized diagnostic tool for CIED endocarditis. At
present, the modified Duke criteria60 and the ESC 2015 criteria59 for
the diagnosis of infective endocarditis are the only available frame-
work for CIED endocarditis diagnosis. However, none represent a
validated and standardized tool for diagnosis in this specific setting. In
order to increase sensitivity for CIED infection diagnosis, this panel
recommends additional criteria and to merge the modified Duke cri-
teria60 and the ESC 201559 criteria. As a result, the 2019 International
CIED Infection Criteria have been developed, and are detailed in
Table 5.
Identification of the causative
microorganisms
Identification of the causative microorganisms for a CIED infection is
pivotal for effective antibiotic therapy (Table 2). Therefore, every ef-
fort should be made to obtain cultures prior to the institution of anti-
biotic therapy. Blood cultures should be repeated in patients with
CIED and fever without clear signs of local infections and infective en-
docarditis. Three sets of blood cultures should be taken (at least
30 min in between) prior to starting antibiotic therapy (Table 6).
Multiple blood cultures at different time intervals enable a distinction
between transient and persistent bacteraemia and increases sensitiv-
ity. In stable patients, a 2–3 days washout period free from antibiotic
therapy may increase precision of microbiological diagnosis. In unsta-
ble patients with sepsis or septic shock, early empiric antibiotic ther-
apy should be administered following two sets of blood cultures thus
not delaying start of antibiotic therapy. Blood bottles must be filled
EHRA position paper 516i
properly in order to increase the sensitivity.17,65 An aseptic technique
for blood culture is mandatory since bacteria mostly considered as
skin contaminants often are the causative agents of CIED infections.
Every positive blood culture, including a single bottle with CoNS or
other Gram-positive organisms, should be carefully evaluated and
prompt active exclusion of CIED infection with other diagnostic tech-
niques employed (Figure 2).71 In case of negative blood cultures
(usually 5 days), increased incubation time (10–14 days) and the use
of biomolecular methods (DNA amplification and/or gene sequenc-
ing) to detect fastidious or atypical pathogenes19 may be considered
for CIED endocarditis and persistent negative blood cultures
(Table 6).67 Among Gram-positive microorganisms there are species
that may require longer period of incubation, such as Cutibacterium
(previously Propionibacterium) acnes, especially in anaerobic
....................................................................................................................................................................................................................
Table 5 Recommendations for diagnosis of CIED infections and/or infective endocarditis: the Novel 2019
International CIED Infection Criteria
Consensus statement Statement class Scientific evidence coding Reference
‘Definite’ CIED clinical pocket/generator infection = generator pocket shows swelling, erythema, warmth, pain, and purulent discharge/sinus
formation OR deformation of pocket, adherence and threatened erosion OR exposed generator or proximal leads
‘Definite’ CIED/IE = presence of either 2 major criteria or 1 major þ 3 minor criteria
‘Possible’ CIED/IE = presence of either 1 major þ 1 minor criteria or 3 minor criteria
‘Rejected’ CIED/IE diagnosis = patients who did not meet the aforementioned criteria for IE
Major criteria E 59
Microbiology A. Blood cultures positive for typical microorganisms found in CIED infection and/or IE
(Coagulase-negative staphylococci, S. aureus)
B. Microorganisms consistent with IE from 2 separate blood cultures:
a. Viridans streptococci, Streptococcus gallolyticus (S. bovis), HACEK group, S. aureus; or
b. Community-acquired enterococci, in the absence of a primary focus
C. Microorganisms consistent with IE from persistently positive blood cultures:
a. >_2 positive blood cultures of blood samples drawn >12 h apart; or
b. All of 3 or a majority of >_4 separate cultures of blood (first and last samples drawn >_1 h apart); or
c. Single positive blood culture for Coxiella burnetii or phase I IgG antibody titre >1:800
Imaging positive for CIED
infections and/or IE
D. Echocardiogram (including ICE) positive for:
a. CIED infection:
i. Clinical pocket/generator infection
ii. Lead-vegetation
b. Valve IE
i. Vegetations
ii. Abscess, pseudoaneurysm, intracardiac fistula
iii. Valvular perforation or aneurysm
iv. New partial dehiscence of prosthetic valve
E. [18F]FDG PET/CT (caution should be taken in case of recent implants) or radiolabelled WBC
SPECT/CT detection of abnormal activity at pocket/generator site, along leads or at valve site
F. Definite paravalvular leakage by cardiac CT
Minor criteria E 59
a. Predisposition such as predisposing heart condition (e.g. new onset tricuspid valve regurgitation) or injection drug use
b. Fever (temperature >38C)
c. Vascular phenomena (including those detected only by imaging): major arterial emboli, septic pulmonary embolisms, infectious (mycotic) aneurysm, in-
tracranial haemorrhage, conjunctival haemorrhages, and Janeway’s lesions
d. Microbiological evidence: positive blood culture which does not meet a major criterion as noted above or serological evidence of active infection with
organism consistent with IE or pocket culture or leads culture (extracted by non-infected pocket)
Based on merging of the modified Duke and ESC 2015 Guidelines criteria, see text.59,60 Green text refers to CIED-related infection criteria.
CIED, cardiac implantable electronic device; CT, computerized tomography; E, expert opinion; ICE, intracardiac echocardiography; IE, infective endocarditis; M, meta-analysis;
O, observational studies; R, randomized trials; SPECT, single-photon emission tomography; WBC, white blood cell.
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condition.19 It has been postulated that S. aureus may be associated
with earlier infections and with infective endocarditis compared to
other pathogens, but data are still inconsistent. More severe cases
may be due to S. aureus and Gram-negative rods.
Swabs collected from the chronic draining sinus or fistula for cul-
ture are discouraged (Table 6). Instead, tissue or fluid collected from
the pocket via an adjacent intact portion of the skin (via a sterile nee-
dle or syringe) is encouraged avoiding passing through the sinus. This
approach should only be used to make a bacterial diagnosis, not to
determine the presence of a pocket infection. Entering an intact
pocket should be avoided to avoid inoculation with bacteria.
During an extraction procedure, distal and proximal lead frag-
ments, lead vegetation if present and generator pocket tissue should
be sent for culture (Table 6).71 Gram stain is still encouraged and bio-
molecular methods are increasingly used and may be more specific.
Culture media suggested are chocolate agar incubated in 5% CO2 for
48–72 h, MacConkey agar incubated for 48 h, blood agar in anaerobic
condition for 48–72 h, and Sabouraud agar incubated for 5 days.72,73
A close collaboration with the local Microbiology Laboratory is im-
portant to increase diagnostic yield. In case of pus, but no growth af-
ter 3 days, consider slow-growing microorganisms including C. acnes
and increase incubation duration. In addition to swabs, tissue samples
and sonication for the recovery of bacteria from CIED leads and tis-
sue, may be useful in patients with clinical signs of infection although
the method merits further investigational study.68–70
Imaging
Echocardiography
Echocardiography should be the first imaging tool in the assessment
of patients with CIED in order to identify lead vegetations and valvu-
lar involvement.59 Transthoracic- (TTE) and transoesophageal echo-
cardiography (TEE) are both recommended in case of suspected
CIED infections. While TTE better defines pericardial effusion, ven-
tricular dysfunction, and pulmonary vascular pressure, TEE is superior
for the detection and sizing of vegetations74 especially in the right
atrium-superior vena cava area and in regions less well visualized by
TTE. In the absence of typical vegetations of measurable size, both
TTE and TEE may be false negative in CIED-related infective endocar-
ditis. Lead masses in asymptomatic CIED carriers may be observed
on TTE/TEE and do not predict CIED-related infective endocarditis
over long-term follow-up.75,76 Therefore, once a lead mass is identi-
fied, careful clinical assessment to rule out either infection or non-
bacterial lead-thrombotic endocarditis is needed, including serial
TTE/TEE or additional imaging tests.
Intracardiac echocardiography (ICE) is effective and has a high sen-
sitivity for the detection of vegetations in cardiac devices.77,78
Therefore, a vegetation seen with ICE may be considered a major cri-
terion for diagnosis (Table 5). Recently, transvenous biopsy, guided
by TEE, was shown to be useful to differentiate vegetation from
thrombus.79
....................................................................................................................................................................................................................
Table 6 Recommendations for diagnosis of CIED infections by clinical findings and microbiology
Consensus statement Statement class Scientific evidence
coding
References
At least three sets of blood cultures should be acquired in case of clinically sus-
pected CIED endocarditis
E, O 19,65
Samples from the pocket should be cultured but only if acquired during removal
and not passing through the sinus
E, O 19,65
Suspect CIED infections in case of vertebral osteomyelitis and/or embolic pneu-
monia (clinical signs and symptoms of CIED systemic infections may be difficult
to recognize as only fever may be present)
E, O 61,65
Cultures of extracted CIED should be performed E, O 66
PCT may be useful in case of infective endocarditis and embolism and/or in case
of S. aureus CIED-related infective endocarditis
E, O 64
Increased incubation time (10–14 days) for slowly-growing microorganism may
be considered in case of CIED-related infective endocarditis and persistent neg-
ative blood cultures
E 67
The usefulness of sonication of CIED to enhance microbial detection during re-
moval/extraction is still under evaluation but may be used with caution when
interpreting results
E, O 68–70
Cultures from the sinus of the CIED pocket or from parts of the device exposed E 19
CIED, cardiac implantable electronic device; E, expert opinion; M, meta-analysis; O, observational studies; PCT, procalcitonin; R, randomized trials.
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In patients with CIED infections treated with percutaneous lead
extraction, a TTE before hospital discharge is recommended to de-
tect retained segments of the pacemaker lead, and to assess tricuspid
valve function, right ventricular function, and pulmonary hyperten-
sion. A TEE (and additional imaging tests) should be considered after
percutaneous lead extraction in order to detect infected material,
ghosts,80 and potential tricuspid valve complications, particularly in
patients with persistent sepsis after extraction (Table 7). It is impor-
tant to remember a normal echocardiography does not rule out
CIED-related infective endocarditis.
Radiolabelled leucocyte scintigraphy, positron emission
tomography, and computerized tomography
Fluorine-18-fludeoxyglucose ([18F]FDG) positron emission tomogra-
phy/computerized tomography (PET/CT) scanning and radiolabelled
leucocyte (WBC) scintigraphy are complementary tools for the diag-
nosis of CIED-related infections and related complications in com-
plex cases. Both imaging techniques provide additional diagnostic
value, particularly in the subset of possible CIED infections, and may
distinguish between early-onset superficial surgical site infection and
a true generator pocket infection or differentiate between superficial
and deep pocket infection. When patients only present with systemic
infection without local findings at the generator pocket the diagnosis
of device lead infection can be challenging and a [18F]FDG PET/CT is
in this situation useful for the diagnosis of local infection [pooled spe-
cificity and sensitivity of 93% (95% CI 84–98%) and 98% (95% CI 88–
100%), respectively, and AUC of 0.98 at ROC analysis].85,99 Mild in-
flammatory changes after device implantation usually do not extend
beyond 6 weeks and are easily differentiated from infection after this
period. White blood cell scintigraphy including single-photon emis-
sion tomography/computerized tomography (SPECT/CT) has high
sensitivity and specificity for the detection and localization of CIED-
related infections (94% and 100%, respectively, in the largest study).89
In case of CIED-related infective endocarditis, [18F]FDG PET/CT and
WBC are very specific when tracer uptake is visualized (only if ap-
plied late after implantation), although a negative result does not
completely exclude the presence of small vegetations with low meta-
bolic activity (i.e. limited sensitivity and negative predictive value).
Therefore, the diagnostic accuracy for lead infections is lower,99,100
with overall pooled sensitivity of 65% (95% CI 53–76%), specificity of
88% (95% CI 77–94%), and AUC of 0.861.
[18F]FDG PET/CT has the ability of whole-body evaluation, so has
proven particularly useful for the identification of unexpected em-
bolic localizations and metastatic infections,84,88 including mycotic
aneurysms, spleen and lung embolisms, and spondylodiscitis (not
brain emboli). This impacts the Duke criteria, the diagnostic certainty,
and therapeutic management. Moreover, the identification of the in-
fection entry site by PET/CT and WBC imaging is critical for the pre-
vention of infective endocarditis relapse.90 Positron emission
tomography/computerized tomography imaging may also contribute
to mortality risk stratification assessment after lead extraction.
Patients with definite CIED infection without pocket involvement on
[18F]FDG PET/CT had unfavourable outcome, suggesting that the
presence of an endovascular infection stemming from an unrecog-
nized/distant site is associated with poor prognosis.101
Posive blood culture
Definite CIED infecon
Negave blood culture*
Look for alternave 
diagnosis
Repeat blood culture/echo
Consider other imaging methods  
Within 2 weeks
Pocket clinically negavePocket clinically posive Pocket clinically posive li i ll  i
Removal/Extracon + Anbioc therapy
(see figure 3) 
Oponal/Consider:
1. [18F]FDG PET/CT or WBC SPECT/CT 
(extent disease, portal of entry, other source)
2. ICE
3. Imaging for embolic events
TTE + TEE
Clinical suspicion of CIED infecon - use 2019 Internaonal CIED Infecon Criteria (Table 5)li ic l s s ici  f I  i f c  - s   I t r l I  I f c  rit ri  ( l  )
Superficial incisional infecon 
Conservave treatment
(see figure 3)
Assess 2019 Internaonal CIED Infecon Criteria (see Table 5)
Pocket clinically negave,
but high suspicion
Rejected CIED infecon
TTE + TEE
Removal / Extracon + 
Anbioc therapy
(see figure 3) 
Refer paent to a center with CIED infecon/extracon expertise
Possible CIED infecon
1.TTE + TEE
2. [18F]FDG PET/CT or WBC  SPECT/CT 
(extent disease, Portal of  Entry, other  source)
3. ICE
4. Imaging for embolic events
Figure 2 Diagnostic algorithm for diagnosis of suspected CIED infections. *, ensure sufficient number of blood cultures collected and absence of
confounding antibiotic therapy prior to cultures. CIED, cardiac implantable electronic device; [18F]FDG PET/CT, fluorodeoxyglucose positron emis-
sion tomography—computed tomography; ICE, Intracardiac echocardiography; IE, infective endocarditis, TEE, transoesophageal echocardiography;
TTE, transthoracic echocardiography; WBC SPECT/CT, white blood cell single-photon emission computed tomography—computed tomography.
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Table 7 Recommendations for diagnosis of CIED infections by imaging59
Consensus statement Statement class Scientific
evidence coding
References
TTE is recommended as the first-line imaging modality in patients with suspected
CIED-related IE
O 81
A chest X-ray should be performed in all patients with suspected CIED infection E
TEE is recommended in suspected CIED infection with positive or negative blood
cultures, independent of TTE results before an extraction, to evaluate CIED in-
fection and IE
O 74
Repeat TTE and/or TEE within 5–7 days is recommended in case of initially nega-
tive examination when clinical suspicion of CIED-related IE remains high
O 81
TEE should be performed in CIED patients with S. aureus bacteraemia O 82,83
ICE may be considered if suspected CIED-related IE, with positive blood cultures
and negative TTE and TEE results
O, E 77,78
[18F]FDG PET/CT scanning or radiolabelled WBC scintigraphy or contrast en-
hanced CT are recommended if suspected CIED-related IE, positive blood cul-
tures, and negative echocardiography (attention in imaging interpretation early
after device implant)
O, M 84,85
[18F]FDG PET/CT should be performed in case of S. aureus bacteremia in CIED
patients
O, E 86,87
[18F]FDG PET/CT, radiolabelled WBC scintigraphy and/or contrast enhanced CT
is recommended for identification of unexpected embolic localizations (i.e. lung
embolism) and metastatic infections
O, M 84,88,89
The identification of the infection portal of entry may be considered by [18F]FDG
PET/CT and WBC imaging in order to prevent IE relapse
O, E 84,90
Pulmonary CT angiography is recommended in patients with recurrent
pneumonia
O, E 91
In patients with CIED infection treated with percutaneous lead extraction, TTE/
TEE before hospital discharge are recommended to detect presence of
retained segments of pacemaker lead, and to assess tricuspid valve function, RV
function, and pulmonary hypertension
O 80,92,93
In case of persistent sepsis after device extraction:
- TEE is recommended to identify residual insulation material and local
complications
- [18F]FDG PET/CT, radiolabelled WBC scintigraphy and/or contrast enhanced
CT for better assessment of local extension of the infection and whole body
assessment
O, M 84,94–97
A multidisciplinary team (the Endocarditis Team) is recommended for evaluation
of imaging results
E 98
[18F]FDG PET/CT, fluorine-18-fludeoxyglucose positron emission tomography/computerized tomography scanning; CIED, cardiac implantable electronic device; E, expert opin-
ion; ICE, intracardiac echocardiography; IE, infective endocarditis; M, meta-analysis; O, observational studies; R, randomized trials; RV, right ventricular; TEE, transoesophageal
echocardiography; TTE, transthoracic echocardiography; WBC, white blood cell count.
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Contrast-enhanced CT combined with PET may prove useful in
selected patients. The addition of contrast-enhanced CT to standard
[18F]FDG PET/CT protocol resulted in a high rate of reclassifications
from ‘possible’ to ‘definite’ infective endocarditis, improving the over-
all diagnostic accuracy with or without the Duke criteria in a series of
patients with suspected pulmonary embolism or CIED infections.84
Cardiac CT angiography may also add important remote information
on vascular complications including mycotic aneurysm, arterial em-
boli, and septic pulmonary infarcts, which add to the diagnostic crite-
ria and affect the overall treatment strategy. In addition, pulmonary
CT angiography may be useful in patients with recurrent pneumo-
nia.91 A wider use of contrast-enhanced CT is limited by the deleteri-
ous impact of contrast agents on kidney function particularly as the
patients are exposed to nephrotoxic antibiotic therapy. An extensive
description of the technical aspects and the interpretation criteria for
multimodality imaging has recently been published.85
Multidisciplinary team (the Endocarditis Team) evaluations of im-
aging results are recommended and have been shown to significantly
reduce the 1-year mortality,98 from 18.5% to 8.2%. Figure 2 shows
the proposed diagnostic flow chart for the use of imaging in patients
with suspected CIED infection.
Management of cardiac
implantable electronic device
infections: when, how, and where
Cardiac implantable electronic device
removal
The key aspect to successful treatment of definite CIED infections is
complete removal of all parts of the system and transvenous hard-
ware, including the device and all leads (active, abandoned, epicardial
as well as lead fragments) as well as vascular ports or permanent hae-
modialysis catheter.102,103 This treatment concept applies to systemic
as well as localized CIED pocket infections.81 In a retrospective study
of 416 patients with CIED infections, antibiotic therapy without de-
vice removal was associated with a seven-fold increase in 30-day
mortality (hazard ratio 6.97, 95% confidence interval 1.36–35.60) in
multivariate analysis.104
The timing of the extraction procedure should be without unnec-
essary delay after the diagnosis of CIED infection (Figures 2 and 3) and
should take place at an experienced centre (Table 8). The perfor-
mance of transvenous lead extraction within 3 days after hospitaliza-
tion results in significantly lower in-hospital mortality and shorter
hospitalizations in patients with CIED infections.114 It is important to
note that despite correct treatment with CIED system explantation
and adequate antibiotic therapy, the mortality in patients with sys-
temic infection is significantly higher than in patients with local infec-
tion. Based on the results of the ELECTRa registry,2 systemic
infection was identified as a predictor for increased all-cause mortal-
ity (OR 4.93, 95% CI 2.72–8.93, P< 0.0001).
When applicable, percutaneous transvenous extraction techni-
ques are the methods of first choice (Table 8), since major complica-
tions and mortality at 1 and 12 months in patients undergoing
transvenous lead extraction techniques is significantly lower com-
pared to open surgical approaches.105,115 Transvenous extraction
procedures are even preferred in the presence of lead vegetations
with a diameter of more than 10 mm (Table 8). Small case series have
reported good short-term outcomes of transvenous lead extraction
procedures in patients with large lead vegetations despite a high per-
centage of pulmonary embolism. However, long-term outcomes of
such patients remain unclear.116,117 In patients with vegetations larger
than 20 mm open surgical extraction may be considered.59,81 Even
with transoesophageal echocardiography the vegetation size may be
difficult to assess. Apart from size, the friability of the vegetation
Definite CIED infecon
Isolated pocket infecon 
(negave blood culture)
Without vegetaon on leads or 
valves + pocket infecon 
it t t   l  r 
l  t i f  
CIED endocardis with
vegetaon on leads and/or 
valves + embolism
Removal /Extracon
+ 
Anbioc therapy
10-14 days
Removal /Extracon
+
Anbioc therapy
4 weeks
(2 weeks if negave 
blood culture)
Removal /Extracon
+ 
Anbioc therapy
4-6 weeks
+ oral anbioc therapy FU
If  indicated by secondary 
infecous focus
Superficial incisional infecon 
Anbioc therapy
7 - 10 days
Systemic infecon
CIED Infecon - TherapyI  I f c  - r y
Meets 2019 Internaonal CIED Infecon Criteria (see Table 5)
Figure 3 Therapeutic strategies for patients with CIED infections. CIED, cardiac implantable electronic device; FU, follow-up; IE, infective
endocarditis.
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should be taken into consideration when planning a procedure. A
promising concept in patients with systemic CIED infection and very
large lead vegetations is percutaneous aspiration of lead vegetations
with the help of a veno-venous extracorporeal circuit with an in-line
filter.106,107 The goal of this treatment is to reduce the overall
‘vegetative’ burden and the risk of embolization of infectious material
into the pulmonary circulation, which may be a source of ongoing
septic complications.
In case of infections of CIED systems with epicardial leads, com-
plete removal of such leads is recommended in case of definite
....................................................................................................................................................................................................................
Table 8 Recommendations for device and lead removal
Consensus statement Statement class Scientific
evidence coding
References
In patients with definite CIED infection (systemic and local), complete device re-
moval is recommended (including abandoned leads, epicardial leads, and lead
fragments)
O 81,102,104
After diagnosis of CIED infection, the device removal procedure should be per-
formed without unnecessary delay (ideally within 3 days)
O 104
The recommended technique for device system removal is percutaneous,
transvenous extraction technique. Epicardial leads require surgical removal
O 105
In patients with systemic infection and lead vegetations of approximately >20
mm, percutaneous aspiration of vegetations prior to and during transvenous
lead extraction or alternatively surgical extraction may be considered
O 105–107
After device removal, meticulous debridement of the generator pocket (complete
excision of the fibrotic capsule and complete removal of all non-absorbable su-
ture material) and subsequent wound irrigation with sterile normal saline solu-
tion is recommended
E 108
Cultures of extracted CIED should be performed E, O 66
The following wound closure methods after device removal and debridement of
device pocket may be performed:
- Primary closure with or without the use of a drain
- Delayed closure after negative pressure wound therapy
E NA
Complete CIED removal is indicated in bacteraemia or fungaemia with S. aureus,
CoNS, Cutibacterium spp., and Candida spp
E 109
In bacteraemia with alpha- or beta-haemolytic Streptococcus spp. and Enterococcus
spp., a complete CIED removal may be performed as first-line treatment or in
case of recurrent/continued bacteraemia despite appropriate antibiotic therapy
as a second step therapy
E 110
In case of bacteraemia with non-pseudomonal/Serratia Gram-negative bacteria or
Pneumococcus spp., CIED removal should be performed in the case of recur-
rent/continued bacteraemia despite appropriate antibiotic therapy when there
is no other identifiable source for recurrence or continued infection
E 14,72,111,112
Complete CIED removal is recommended in patients with infective endocarditis
with or without definite involvement of the CIED system
E 113
Blood cultures should be taken 48–72 h after removal of an infected CIED E 19
CIED, cardiac implantable electronic device; E, expert opinion; M, meta-analysis; NA, not available; O, observational studies; R, randomized trials.
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involvement based on individual risk–risk-analysis (operative risk of
epicardial lead removal vs. infection-related mortality risk).115 In case
of localized pocket infection of a CIED system without definite in-
volvement of the distal portion of an epicardial lead, it is reasonable to
leave the distal portion of the epicardial lead in place by cutting the
lead through a separate incision away from the device pocket and re-
moving the proximal part of the lead through the pocket.81 [18F]FDG/
PET/CT scan may prove helpful in assessing such special situations.
In cases of occult bacteraemia or fungaemia, the results of microbi-
ological examination influence further therapy. Complete CIED re-
moval is indicated in bacteraemia or fungaemia with S. aureus, CoNS,
Cutibacterium spp., and Candida spp. In bacteraemia with alpha- or
beta-haemolytic Streptococcus spp. and Enterococcus spp. complete
CIED removal may be carried out as first-line treatment or as a
second step in case of recurrent/continued bacteraemia despite ap-
propriate antibiotic therapy. In case of bacteraemia with non-
pseudomonal/Serratia Gram-negative bacteria or Pneumococci an
appropriate antibiotic therapy is indicated first. In case of recurrent/
continued bacteraemia, complete CIED removal should be per-
formed in cases when no other identifiable source for recurrence or
continued infection is found.14,72,102,111,112 Complete CIED removal
is furthermore indicated in patients with infective endocarditis with-
out definite involvement of the CIED system.113
After device and lead removal a meticulous debridement of the
device pocket with complete excision of the fibrotic capsule as well
as removal of all non-absorbable suture material and subsequent
wound irrigation with sterile normal saline solution is crucial.
Irrigation with antibiotic solution does not offer any significant advan-
tage over irrigation with saline solution.108 Wound closure concepts
may be primary closure with or without the use of a drain or alterna-
tively delayed closure utilizing negative pressure wound therapy.
Cardiac implantable electronic device patients with superficial
wound infections early after implantation, device exchange or revi-
sion surgery should not undergo device and lead removal. Superficial
infections are confined to the skin and the subcutaneous tissue with-
out involvement of any parts of the CIED system. The differentiation
between a superficial and a pocket infection can be a clinical chal-
lenge. Therefore, it is important to closely watch patients who are
under suspicion of having a superficial infection. In such patients, an
oral antibiotic therapy (7–10 days) is reasonable.65
Antimicrobial therapy including
long-term suppressive therapy
Definitive treatment of CIED infection is early and complete removal
of all parts of the system and antibiotic therapy is to be seen as a com-
plement to treat associated systemic infection and to cure the remain-
ing infection in native tissues.103 Randomized controlled studies to
guide antibiotic choice in CIED infections are lacking and recommen-
dations are based on cohort studies, case series, expert opinion, and
pharmacological considerations.19,59,65 Access to timely device re-
moval influences antibiotic therapy and treatment regimens also differ
between countries depending on the prevalence of MRSA, other dif-
ferences in antibiotic resistance patterns, and access to specific antibi-
otics including newer substances. Antibiotic combination therapy with
rifampicin targeting biofilm-associated staphylococcal infection is not
recommended when the device will be removed unless a concomitant
foreign body associated infection, i.e. a prosthetic valve endocarditis
that is not amenable to replacement surgery, is present. Antibiotic
treatment alone is not recommended for CIED infections but individ-
ual patients may not be candidates for device removal. Successful sal-
vage therapy has been reported in a minority of patients.103 Long-term
suppressive antibiotic therapy is also used in selected cases.118
Antibiotic treatment recommendations including empirical choices
for the three major categories of CIED infections, superficial inci-
sional infection, isolated device pocket infection, and systemic infec-
tions, are summarized in Table 9. Systemic infections are further
divided depending on presence of positive blood cultures and vegeta-
tions on leads and/or valves.65
For superficial incisional infection, a wound culture before initiation
of antibiotic treatment is recommended (Table 9).
For isolated pocket infections empirical i.v. therapy is recommended
after blood cultures have been obtained (Table 9, Figure 3). Definitive
treatment should be given according to culture result with an appro-
priate antibiotic with a narrow spectrum, if possible a betalactam anti-
biotic. Combination therapy is not needed. A switch to oral
treatment after device removal is reasonable since the remaining in-
fection only involves skin and soft tissue, but evidence-based recom-
mendations are lacking. In pocket erosion with minimal inflammation,
delayed antibiotic therapy until after device removal and pocket cul-
tures should be considered.
For pocket infection with positive blood culture but without vegetation on
leads or valves, the definite treatment follows recommendations given
above but the systemic involvement makes a switch to an oral antibi-
otic regimen inappropriate (Table 9, Figure 3). Shorter post-extraction
treatment duration is considered possible by some experts.19
For blood culture positive CIED endocarditis with vegetation on lead or
valve the recommendations follow guidelines for infective endocardi-
tis (Table 9).59 If the TEE performed after device removal shows no
signs of valve vegetation (i.e. isolated lead vegetation), the follow-up
blood cultures are negative, the clinical improvement is good and
there are no pulmonary abscesses, treatment duration for 2 weeks
post-device extraction can be sufficient but total treatment duration
should not be shorter than 4 weeks (Figure 3).
For bacteraemia in a CIED patient without signs of pocket infection or
echocardiographic evidence of lead or valve involvement, the antibiotic
treatment follows general recommendations. Due to the risk of
undetected device infection, device removal should be considered
even in the absence of vegetations, in case of infection with specific
pathogens or relapsing bacteraemia without other source, but ran-
domized studies are lacking.119 The addition of rifampicin is not rec-
ommended in patients with S. aureus bacteraemia but can be
considered in the presence of concomitant non-removable foreign
body.120,121 For S. aureus, CoNS, Cutibacterium spp., and Candida spp.,
CIED removal is generally recommended. With viridans group and
beta-haemolytic Streptococcus spp. or Enterococcus spp., device re-
moval should be considered as well as prolonged i.v. treatment
(4 weeks). Even though Gram-negative bacteria are capable of sec-
ondary seeding of a device,72 concomitant CIED infection is uncom-
mon in non-pseudomonal/Serratia Gram-negative or pneumococcal
bacteraemia, and device removal is generally not needed.14,111,112
For attempted salvage therapy if complete device removal is not possi-
ble, long-term suppressive therapy with i.v. antibiotic following rec-
ommendations in prosthetic valve endocarditis for 4–6 weeks is
reasonable (Table 9, Figure 3). If oral suppressive therapy is planned,
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Table 9 International consensus recommendations for antibiotic therapy including long-term suppressive therapy
Consensus statement Statement
class
Scientific
evidence
coding
References
Superficial incisional infection
Empirical treatment:
Oral antibiotic treatment covering S. aureus
Flucloxacillin oral (amoxicillin-clavulanate is an alternative)
If high MRSA prevalence: Trimethoprim-sulfamethoxazole,
Clindamycin, Doxycyclin, Linezolid
To be adjusted after culture result
Duration: 7–10 days
Flucloxacillin p.o. 1 g every 6–8 h
(amoxicillin-clavulanate standard dose)
O, R 19,65
Isolated pocket infection (negative blood cultures)
Empirical treatment:
Directed at methicillin-resistant coagulase-negative staphy-
lococci (CoNS) and S. aureus:
Vancomycin (Daptomycin is an alternative)
If systemic symptoms:
For additional Gram-negative coverage, combine with 3rd
generation Cephalosporin (or a broader betalactam anti-
biotic) or Gentamicin
To be adjusted after culture result
If sensitive staphylococcus: Flucloxacillin (1st generation
cephalosporin as an alternative)
Partial oral treatment often used
Duration post-extraction: 10–14 days
Vancomycin: 30–60 mg/kg/d i.v. in 2–3
doses (Daptomycin 8–10 mg/kg i.v. od)
þ/-
Cephalosporin: standard dose
Gentamicin 5–7 mg/kg i.v od**
Flucloxacillin: 8 g/d i.v. in 4 doses or
(1st generation cephalosporin standard
dose)
O, R 19,59,65
Systemic infections
Without vegetation on leads or valves6 pocket infection
Empirical treatment: (directed at methicillin-resistant staph-
ylococci and Gram-negative bacteria):
Vancomycin (Daptomycin is an alternative)
þ 3rd generation Cephalosporin (or a broader betalactam
antibiotic) or Gentamicin
To be adjusted after culture result
If sensitive staphylococcus: Flucloxacillin i.v. (1st generation
cephalosporin i.v. as an alternative)
Duration post-extraction: 4 weeks (2 weeks if negative
blood culture, see text)
Vancomycin: 30–60 mg/kg/d i.v. in 2–3
doses (Daptomycin 8–10 mg/kg od)
þ
Cephalosporin: standard dose i.v or
Gentamicin 5–7 mg/kg i.v. odb
Flucloxacillin i.v. dosages as above.
(1st generation cephalosporin standard
dose i.v.)
O, R 19,59,65,81
CIED endocarditis with vegetation on leads and/or valves6 embolism
Empirical treatment:
Vancomycin (Daptomycin is an alternative)
þ 3rd generation Cephalosporin (or a broader betalactam
antibiotic) or Gentamicin
Adjust to culture result according to ESC endocarditis
guidelines 2015
If prosthetic valve and staphylococcal infection: Rifampicin
to be added after 5–7 days
Vancomycin; 30–60 mg/kg/d i.v. in
2–3 doses (Daptomycin 8–10 mg/kg
od)
þ
Cephalosporin; standard dose or
Gentamicin 5–7 mg/kg i.v. odb
Rifampicin: 900–1200 mg/day orally (or
i.v.) in 2 doses
O, R 59
Continued
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antibiotic therapy should be chosen according to culture results but
evidence-based recommendations cannot be made.103,118 In
methicillin-sensitive staphylococci, oral flucloxacillin is considered an
option by some experts but is not used by others due to low oral
bioavailability. In methicillin-resistant S. aureus or CoNS, oral trimeth-
oprim-sulfamethoxazole, clindamycin, or doxycyclin (if sensitive) are
alternatives. Linezolid is not suitable for long-term treatment.
Rifampicin and fusidic acid are not suitable as single therapy. A combi-
nation of suppressive therapy is generally not preferred. The treat-
ment duration needs to be individualized.
Preventive strategies after
cardiac implantable electronic
device implantations, new
re-implantations, and alternative
novel devices
Preventive strategies after cardiac
implantable electronic device
implantations
Since the removal or extraction of CIEDs is usually mandated if infec-
tion occurs, prevention of infection is a key goal. While primary pre-
vention measures, including prophylactic antibiotic therapy,21
appropriate infection control measures, and careful surgical tech-
nique, are well established and highly recommended, data supporting
the benefits of secondary prophylaxis are relatively scarce and con-
troversial. Early follow-up in a clinical setting and thorough patient ed-
ucational programs should be conducted for early identification of
CIED-related infectious complications, including video consultations
for wound inspections. A short period of treatment may prevent pro-
gression, but may also mask a pocket infection, delay appropriate
treatment, or expose the patient to unnecessary medical therapy.
At present, there is no convincing evidence that microorganisms
associated with invasive medical procedures cause infection of non-
valvular vascular devices at any time after implantation (Table 10).
Therefore, antibiotic prophylaxis is not routinely recommended for
CIED patients who undergo dental, respiratory, gastrointestinal, geni-
tourinary, or cardiac procedures. Secondary prophylaxis is only rec-
ommended for patients when they undergo incision and drainage of
infection at other sites or replacement of an infected device.134
Re-implantations
All established CIED infections, systemic or localized, mandate com-
plete hardware removal and no part of the removed CIED should be
re-implanted. This also applies to the venous access sheath used for
percutaneous removal, which should not be used for re-implantation
of a new system. Central and peripheral lines and any other remov-
able catheters should also be changed at this time, where feasible.
The indication for re-implantation should always be re-evaluated
after a CIED removal.38,122 A different device than the previous one
may be the most optimal choice or there may be no absolute indica-
tion for re-implantation at the time of lead extraction. There are no
randomized trials guiding appropriate timing of re-implantation and
therefore such decision must be individualized. Re-implantation
should be delayed until signs and symptoms of local and systemic in-
fection have resolved or postponed until blood cultures are negative
for at least 72 h after the extraction if feasible (Table 10).38,123,135 In
pacemaker-dependent patients, it seems reasonable to use temporary
....................................................................................................................................................................................................................
Table 9 Continued
Consensus statement Statement
class
Scientific
evidence
coding
References
Duration for native valve infective endocarditis: 4 weeks
post extraction, for prosthetic valve endocarditis: (4-) 6
weeks, for isolated lead vegetation: 2 weeks therapy after
extraction may be sufficient (in total 4 weeks) except for
S. aureus infection, see text
Bacteraemia in a CIED patient without signs of pocket infection or echocardiographic evidence of lead or valve involvement
According to pathogen specific treatment guidelines, see
text
O, R 119,120
Attempted salvage therapy and long-term suppressive therapy
I.v. antibiotics as in prosthetic valve endocarditis for 4–6
weeks
Stop antibiotic therapy under close follow-up or con-
tinue individualized long-term suppressive oral therapy,
see text
E 103,118
aTreatment regimens differ between countries depending on prevalence of MRSA and other circumstances—see text. Dosage recommendation needs to be adjusted for kidney function.
bFor patients with normal renal function.
d, day; E, expert opinion; H, hour; i.v., intravenous; M, meta-analysis; MRSA, methicillin-resistant Staphylococcus aureus; O, observational studies; od, once daily; p.o., per oral; R,
randomized trials.
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pacing until symptoms and signs of systemic infection have resolved
before implanting a permanent device. An active-fixation lead ipsilater-
ally implanted, albeit preferably not through the vein from which the
infected lead was extracted, and connected to an externalized pace-
maker could be the best strategy in order to safely delay re-implanta-
tion124–127 by keeping the infected extraction side for temporary
pacing and preserving the contralateral side for definitive device re-im-
plantation.57,81,128 Epicardial lead placement has been used for decades
as the only reliably strategy for patients at very high risk of re-infection.
Alternative novel devices
Leadless pacemakers (LPM) and S-ICD are excellent alternatives to
traditional CIEDs. Currently, two self-contained right ventricular
pacemakers implanted by using a femoral percutaneous approach
have been developed: MicraTM Transcatheter Pacing System (TPS;
Medtronic, Minneapolis, MN, USA) and NanostimTM Leadless
Cardiac Pacemaker (LCP; St. Jude Medical, Sylmar, CA, USA), al-
though only the former is currently available for clinical use. It can
pace the right ventricle with a rate response technology and may rep-
resent a valid and alternative solution, if indication is appropriate. No
infection occurred after a short/mid-term follow-up.129 In selected
high-risk patients, the risk of infection with LPM appears low.41 The
device also seems safe and feasible in patients with pre-existing CIED
infection and after extraction of infected leads.130,136
Similarly, S-ICD has proven to be safe and effective in many clinical
trials in detecting, discriminating, and terminating potentially life-
threatening ventricular arrhythmias, even if it is not able to deliver
anti-tachycardia pacing and can only provide post-shock ventricular
pacing at 50 b.p.m. for 30 s. In selected patients with no need for pac-
ing, ATP or CRT, the re-implantation of a S-ICD significantly reduced
the risk of new infections while still providing an effective and safe de-
fibrillation system.132,133,137 While they do not offer complete pro-
tection against infection, their removal is much simpler and most
often does not result in a life-threatening systemic infection.138 While
randomized trial data are still forthcoming, data from the 985 patients
enrolled into the European EFFORTLESS Registry found an infection
rate (requiring device removal) of 2.4% over 3 years of follow-up.139
In the near future, the LPM and the S-ICD (Boston Scientific) are
expected to integrate wireless intrabody communication between
devices to co-ordinate pacing and antitachycardia therapy delivery.133
For patients with a high risk of sudden cardiac death on short-term
and no need for pacing a wearable defibrillator (LifeVest, Zoll) is an
option as a bridge to re-implantation.
Prognosis, outcomes, and
complications of cardiac
implantable electronic device
infections
Cardiac implantable electronic device infection has an in-hospital or
30-day mortality of 5–8%133,140,141 including mortality from lead
....................................................................................................................................................................................................................
Table 10 Recommendations for preventive strategies after device implantation and for new re-implantations includ-
ing alternative novel devices
Consensus statement Statement class Scientific
evidence coding
References
After device extraction, re-assessment of the indication for re-implantation is
recommended
O 38,122
Whenever possible, re-implantation may be avoided or delayed until symptoms
and signs of systemic and local infection have resolved
O 38,123
A temporary pacemaker with ipsilateral active fixation strategy may be consid-
ered in pacemaker-dependent patients requiring appropriate antibiotic treat-
ment before re-implantation
O 124–127
Preferred access sites for replacement device are the contralateral side, the femo-
ral vein, or epicardially
E, O 38,128,129
Temporary pacing in patients who are not pacemaker dependent O 28
Replacement device implantation ipsilateral to the extraction site E 38
Alternative novel devices as LPM and S-ICD may be considered in selected
patients with high infective risk or in patients in whom these devices are consid-
ered better options after an CIED infection
O 129–133
CIED, cardiac implantable electronic device; E, expert opinion; LPM, leadless pacemaker; M, meta-analysis; O, observational studies; R, randomized trials; S-ICD, subcutaneous
implantable cardiac defibrillator.
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extraction, usually reported as 0.5%,2 but which is principally re-
lated to the complications of ongoing sepsis. The mortality is higher
for patients with significant co-morbidities (e.g. cardiac failure, renal
failure, corticosteroid use), with CIED endocarditis rather than
pocket infection,114 and for patients who do not undergo complete
removal of CIED hardware.118 In-hospital morbidity also comprises
the complications of lead extraction, usually reported as 2–3%, in-
cluding emergency thoracotomy for perforation, arterio-venous fis-
tulae, and tricuspid valve damage; septic pulmonary emboli (1%);
arrhythmias; and ongoing sepsis.2 Following device removal, compli-
cations can arise from the re-implantation of a new device, particu-
larly recurrent infection, although uncommon provided appropriate
antibiotic treatment and timing of the new implant.
Patients who do not have complete removal of hardware, particu-
larly because they are considered too frail, have a very high mortality
in-hospital and over the months following discharge.118,142 A delay in
device removal also leads to a worse prognosis.114
The long-term mortality in patients following CIED infection is up
to 1.5–2.4 times the mortality rate of non-infected patients,140,143
which is 6–15% at 1 year and 14–33% at 3 years, the range of esti-
mates reflecting the age and co-morbidities of the patients being stud-
ied. Patients with infective endocarditis144,145 and females have a
higher long-term mortality rate than males,146 when adjusted for co-
morbid factors. The presence of end-stage renal failure confers a par-
ticularly poor prognosis.147 However, it is not clear whether the
higher long-term mortality is due to the CIED infection itself, or to
the presence of poor prognostic factors in the patients who develop
CIED infection (e.g. cardiac failure, renal failure, coagulopathy, corti-
costeroid use, diabetes), or whether a poor outcome reflects inade-
quate management. There is some indication that patients who have
been successfully treated (‘cured’) with complete removal of hard-
ware and a full course of antibiotics may have a similar prognosis to
patients who have never been infected.148,149
Special considerations to prevent
device-related infections (elderly,
paediatrics, adult with congenital
heart disease)
Certain patient populations pose additional risks and considerations
for infection prevention. One of these populations are the elderly
patients needing a pacemaker or ICD.150,151 In several studies, age
per se is not an independent predictor of infection when adjusted for
other co-morbidities, such as diabetes, renal failure, heart failure, ma-
lignancy, and pulmonary disease.5,22,28,152,153 Frailty, common in the
elderly, is associated with worse cardiovascular outcomes.154,155
Cardiac implantable electronic device patients with decreased mobil-
ity and decreased activity are more likely to be frail.156 In a study of
nearly 84 000 patients followed in the National Cardiovascular
Device Registry-ICD (NCDR-ICD), combinations of frailty with
other known risk factors for CIED infections were predictive of
higher mortality.155 The elderly are often at greater risk of device
erosion due to the loss of subcutaneous tissue and muscle mass.81,157
Using a sub-muscular approach may provide better protection
against erosion in appropriate patients. There are several surgical
approaches to the sub-muscular space and implanting physicians
should be familiar with these.158 As in all patients, careful attention to
haemostasis is important, as haematoma is a consistent risk factor for
infection.7,24
Younger age also has been associated with a higher risk of CIED in-
fection. In a study of 46 299 patients enrolled in the Danish
Pacemaker Register, 2499 (5%) of patients were under the age of
20 years. In multivariate analysis, age under 20 years was found to
have a 40% higher risk for infection (HR 1.41, 95% confidence interval
0.83–2.38).3 The higher risk of infections may be due to the total
number and complexity of device-related procedures that a young
person is exposed to over the course of their life.152,159,160
Colonization of the pocket may lead to higher rates of infections with
subsequent generator replacements.161 The complication rates of
procedures involving lead revisions or replacements is reported to
be at least twice higher than that of de novo implants.21,22,28,162 In one
study of 497 children receiving pacemakers over a 20-year period
with median follow-up of 6 years, the lead failure rate was 15%, which
occurred in 23% of the patients. Over a quarter (28%) of the patients
experienced multiple failed leads. Risk of lead failure was associated
with age <12 years at implant, congenital heart disease (CHD), and
epicardial lead placement. The reported infection rate after lead re-
placement in this study was 1.9%.163
Data from the NCDR-ICD note low (0.2%) acute infection rates
in adults with congenital heart disease (ACHD) patients.164 As in
adults, most infections in paediatric ages and CHD present after
longer-term follow-ups and appear to be in a similar range as that
reported in adults (1–5% serious infections).3,145,151,152,159,165,166 In
one retrospective registry study of 443 ICD paediatric or CHD
patients, the 30-day and longer than 30-day cumulative infection rate
was 4.9%.165 While lead extraction is reported to have high success
in the paediatric and CHD population, nevertheless the serious con-
sequences of CIED-related endocarditis and need for full device sys-
tem extraction are not trivial.159,167
The approach to device implantation poses special challenges in
children and CHD patients. Due to small size, abnormal anatomy,
and restricted venous access, unusual surgical approaches may be re-
quired.168–173 Epicardial pacing leads and submuscular abdominal
positions for the generator are used in the very young with ICD high
voltage leads placed in the posterior-lateral pericardial space. As the
children grow, transition to transvenous PM and ICD systems can oc-
cur if venous access is available. The submuscular (subpectoral) ap-
proach for generator placement has been preferred due to smaller
size and/or cosmetic reasons.174 Regardless of specific approach, the
young paediatric, CHD, and ACHD patients face a lifetime of device
system revisions often resulting in the need for alternative
approaches. An alternative approach for older children needing an
ICD is the S-ICD. The absence of need for transvenous leads may de-
crease device-related complications including infection. A report of
pooled data from the EFFORTLESS registry combined with the
patients enrolled into the US FDA IDE trial showed that no infections
occurred in the 19 patients with CHD (age 12–65) compared with
1.5% system infections in the remaining 846. Overall complications
were similar (10.5% and 9.6%, respectively) over a follow-up about
2 years.175 In a report from the Alliance for Adult Research in
Congenital Cardiology, 21 patients from 7 centres with ACHD re-
ceived a S-ICD. At 14 months of follow-up, a single infection was
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identified which did not require device removal.176 Several additional
reports have demonstrated favourable use of the S-ICD in these
patients.177–179 Pacemakers that are programmed dedicated bipolar
pacing are compatible with the S-ICD system and the combination
has been reported in CHD.180
Recommendations for prevention of infections related to device
implantations in elderly, paediatric patients and patients with ACHD
are outlined in Table 11.
Minimum quality requirements
concerning centres and operator
experience and volume
Data on association between centre volume and operator experience
and volume and the occurrence of CIED infections are scarce and het-
erogeneously reported. Some studies date back to the pre-antibiotic
era, all are observational in nature, and choice of predictors, statistical
adjustments and CIED infection definitions vary widely as do follow-up
periods. The recommendations given on centre and operator volumes
are approximations based on observational data and expert consensus.
For every surgical procedure a learning curve exists during which
complications are expected more frequently. For implantation
of cardiac pacemakers, an operator experience <100 procedures
was associated with higher risk of infection in the pre-prophylactic
antibiotic era.181,182 Less than 100 procedures were also associated
with a higher risk of any complication.183 Pocket haematoma, known
to be associated with higher infection risk, was more common in
patients implanted by operators with <100 procedures experience,
and haematoma requiring re-intervention were more frequent with
operators experience <50 procedures.184 Based upon these reports,
it seems reasonable to recommend close supervision of operators
with less than approximately 100 procedures experience.
Several large observational studies have reported complication
risk for different operator volumes. For ICD implantations, operator
volume <29 procedures per year was associated with adjusted odds
ratio for infection of 2.47 (95% CI 1.18–5.17) compared to higher vol-
ume operators.185 Notably, more high-volume operators also had
higher volume of pacemaker implantations.185 Considering any com-
plication, operator volume <60 procedures per year was associated
with a highly increased risk of complications [hazard ratio 10.4 (1.32–
82.14)] in data from the Ontario ICD database.186 For cardiac pace-
makers, operator volume >40 procedures per year was associated
with fewer complications.187 From a Danish nationwide cohort study
of CIED procedures, annual operators volume <50 procedures was
associated with a 1.9 (1.4–2.6) adjusted risk ratio of any complication,
and higher risk of CIED infection (1.7% vs. 0.5%, P= 0.02).188
Therefore, an annual minimum operator volume of approximately 50
CIED procedures is recommended.
For centre volume, data are even less solid. Centres with lower im-
plantation volume (<250 per year) were reported with higher infec-
tion risk for replacement procedures.7 In historical data from the
Danish Pacemaker Registry, infection rates for cardiac pacemakers
were similar between high-volume university centres and lower vol-
ume centres (<200 procedures per year).3 From a prospective Danish
nationwide cohort, centres with implant volume >750 per year had
the lowest risk of any complication, while infections did not differ be-
tween centre volumes.188 However, the smallest centres in this analy-
sis had up to 249 implants per year. In the Dutch FOLLOWPACE
registry, including centres with mean annual volumes from 53 to 220
procedures, no association between centre volume and risk of any
complication was observed,189 while a large German nationwide analy-
sis clearly indicated an inverse relationship between risk of any early
surgical complications and centre procedure volume.190 Therefore,
any specific recommendation for minimum centre volume will be arbi-
trarily and consensus based. However, a centre needs >_2 implanters,
....................................................................................................................................................................................................................
Table 11 Recommendations for prevention of infections related to device implantations in elderly, paediatric
patients, and in adults with congenital heart disease
Consensus statement Statement class Scientific
evidence coding
References
Implanting physicians should be aware of the higher CIED infection risks in frail
and elderly patients. Submuscular position of PM or ICD generators is recom-
mended in selected elderly patients with limited subcutaneous tissue to prevent
device erosion
O 158
Implanting physicians should be skilled in multiple and alternative surgical
approaches performed in paediatric, congenital heart disease, and ACHD
patients related to a higher risk of CIED infection due to multiple procedures,
lead addition and revisions, and upgrade procedures
M, O 168–172
The entirely S-ICD should be considered as an alternative to transvenous or epi-
cardial approaches in the older child, patients with congenital heart disease,
and those with limited or no venous access. Patients with a bradycardia indica-
tion, anti-tachycardia pacing, or cardiac resynchronization therapy require-
ments are not appropriate candidates
O 175–179
ACHD, adults with congenital heart disease; CIED, cardiac implantable electronic device; ICD, implantable cardiac defibrillator; PM, pacemaker; S-ICD, subcutaneous implant-
able cardiac defibrillator; R, randomized trials; O, observational studies; M, meta-analysis; E, expert opinion.
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each performing >_50–60 procedures. Allowing for training, a minimum
centre volume of approximately 150 procedures per year is therefore
recommended.190 The recommendations on minimum quality require-
ments concerning centres and operator experience and volume are
outlined in Table 12. Every centre should monitor and report local in-
fection rates to a database.
Health economics for cardiac
implantable electronic devices
infections and strategies to
reduce costs
The incidence of CIEDs infections is increasing at a faster rate as com-
pared with device implantation rates.4,153,191 This has important impli-
cations for the healthcare systems in view of induced healthcare costs,
related to a hospitalization usually of 2–4 weeks, with wide use of anti-
biotics and need for procedures for device removal and lead extrac-
tion, as well as CIED re-implantation.4,6,192 Estimates of the costs of
CIED infection are limited, with reported values of e20 623–e23 234
in France, e36 931 (£30 958) in the UK, and values ranging between
e15 516 and e337 886 ($16 651 to $362 606) in the USA, with the
wide range related to treatment intensity and complexity.6,11,193 For
interpreting these estimates, it is noteworthy to consider that any
added day of in-hospital stay has huge costs, ranging from $476–835 in
European countries to $4287 (on average) in the USA.194
In view of these costs, it is critical that the reimbursement tariffs
properly cover the costs due to management of CIED infection
patients in all the involved centres. In Europe, reimbursement practices
usually are based on Diagnosis Related Groups and show an important
variability for device procedures,195 and if that tariff is inadequate, the
reimbursement policy can ‘interfere’ with physician choices in most
complex patients with a substantial risk of suboptimal care.196
Health technology assessment is the specific tool for a compre-
hensive approach to this complex issue, involving all the stakehold-
ers.197,198 Large national and international registries are of crucial
importance for analysing the pattern of referral, the results of lead ex-
traction and the outcomes, in the perspective of optimization of the
chain of care, involving many stakeholders, in a ‘hub and spoke’
organization system which should guarantee expert care, coupling ef-
fectiveness with appropriate use of resources.2,196
Divergent recommendations from
different societies
Strategies for preventing and managing CIED infections vary widely,
and the evidence to guide practice is limited. Until now, guidelines on
how to prevent, diagnose, and treat CIED infections were published
only by the American Heart Association (2010)65 and by the British
Society for Antimicrobial Chemotherapy, British Heart Rhythm
Society, British Cardiovascular Society, British Heart Valve Society,
and British Society of Echocardiography (2015).19
In addition, guidelines for the management of infective endocarditis
were published in 2015 by the European Society of Cardiology
(ESC)59 and by the American Heart Association.199 Recently, the
Heart Rhythm Society (HRS) developed a Consensus Statement on
Cardiovascular Implantable Electronic Device Lead Management and
Extraction providing practical clinical guidance in the broad field of
lead management, including lead infectious process.81 A summary of
the main divergent recommendations across these five guidelines is
available in Table 13.
General definitions and minimal
requirements of variables in
scientific studies and registries
Cardiac devices registries have been used in many centres around
the world; however, a standard dataset definition for patients with
CIED infection remains unavailable. A document dedicated to this
topic regarding lead extractions has been published.57 Adopting stan-
dardized data elements and a standard terminology is arguably the
key to facilitate the exchange of data across studies and to promote
interoperability between different electronic health records sys-
tems.200–202 In addition, standardized outcomes measurement will
probably open up new possibilities to compare performance globally,
providing the medical community with real-world evidence to im-
prove healthcare for patients. A minimum dataset of variables is de-
tailed in Table 14 to serve as a guide when designing CIED infection
....................................................................................................................................................................................................................
Table 12 Recommendations on minimum volume requirements of cardiac implantable electrical device (CIED) pro-
cedures for centres and operators
Consensus statement Statement class Scientific
evidence coding
References
Operators with less than approximately 100 CIED procedures experience should
work under close supervision of more experienced operators
O, E 181–184
An annual minimum operator volume of approximately 50 CIED procedures is
recommended for all operators
O, E 185–188
CIED, cardiac implantable electrical device; E, expert opinion; M, meta-analysis; O, observational studies; R, randomized trials.
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Table 13 Recommendations/guidelines published by different societies on management of cardiac implantable elec-
tronic device infections
Guidelines content Recommendations AHA65
2010
BHRS19
2015
ESC59
2015
AHA199
2015
HRS81
2017
EHRA
2019a
Diagnosis
Transoesophageal echocardiography TEE should be used for diagnosis
since it has higher sensitivity in
establishing intravascular related
CIED infection than TTE
     7
[18F]FDG PET/CT/scintigraphy
with radiolabelled WBC
[18F]-FDG PET/CT/scintigraphy with
radiolabelled WBC should be used
as an additive diagnostic tool
NA Only for
research
 NA  7
Blood cultures Blood cultures should be taken 48–
72 h after removal of infected
CIED
NA  NA NA NA 6
Generator pocket tissue/lead Percutaneous aspiration of generator
pocket should not be performed
 NA NA NA NA 6
Generator pocket tissue/lead Tissue should be excised from
pocket site and sent for culture
NA  NA NA NA 6
Radiography Chest X-ray should be performed if
suspected CIED infection
NA  NA NA NA 7
ceCT/CT pulmonary angiography ceCT or CT pulmonary angiography
should be considered when CIED
infection is suspected and echocar-
diography is non-diagnostic
NA  NA NA NA 7
Treatment—CIED management
Early post-implantation inflammation In superficial or early inflammation,
the CIED can initially be left in situ.
  NA NA NA 8
Isolated pocket infection/erosion The CIED must be removed
completely within 2 weeks after
diagnosis
  NA NA NA 8
CIED lead infection Complete device system must be re-
moved in CIED lead infection.
  NA NA  8
CIED infective endocarditis Complete removal is mandatory in
CIED infective endocarditis
     8
Occult bacteraemia Complete device removal is recom-
mended in occult bacteraemia
 NA NA NA  8
Device reimplantation New transvenous lead implant should
be postponed if possible, to allow
a few days or weeks of antibiotic
therapy
   NA  10
Device reimplantation The replacement device implantation
should not be ipsilateral to extrac-
tion site. Preferred locations are
contralateral side, iliac vein, or
epicardial
  NA NA  10
Treatment—antibiotic strategy
Early post-implantation inflammation In early post-implantation inflamma-
tion, the use of antibiotic therapy
should be determined on a case by
case basis
NA  NA NA NA 9
Uncomplicated pocket infection In uncomplicated pocket infection,
empirical antibiotic therapy can be
used
NA  NA NA NA 9
Complicated pocket infection Duration of antibiotic therapy should
be 10–14 days after CIED removal
for pocket-site infection
 NA NA NA NA 9
Continued
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Table 13 Continued
Guidelines content Recommendations AHA65
2010
BHRS19
2015
ESC59
2015
AHA199
2015
HRS81
2017
EHRA
2019a
Diagnosis
Complicated pocket infection Antibiotic treatment options and du-
ration depend on echo findings; if
no native valve involvement, treat
as uncomplicated generator
pocket infection
NA  NA NA NA 9
CIED lead infection Duration of antibiotic therapy should
be at least 14 days after CIED re-
moval for bloodstream infection
 NA NA NA NA 9
CIED infective endocarditis The duration of antibiotic therapy
should be at least 4–6 weeks for
complicated infection
  NA  NA 9
Antibiotic prophylaxis Systemic antibiotic prophylaxis
should be used prior to CIED
implantation
  NA NA NA 4
Team/reference centre Complicated infective endocarditis
should be referred early and man-
aged in a reference centre with im-
mediate surgical facilities
(‘Endocarditis Team’)
NA NA  NA NA 7
18F-FDG PET/CT, fluorine-18-fludeoxyglucose ([18F]FDG) positron emission tomography-computerized tomography (PET/CT) scanning; CIED, cardiac implantable electronic
device; NA, not available; TEE, transoesophageal echocardiography; TTE, transthoracic echocardiography; , agreed recommendation.
aThe number refers to the table for the recommendation in the present document where the particular subject was addressed.
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Table 14 Minimal study variables for scientific studies and registries
Variable group Data field Value domain
Hospital characteristics
Lead extraction reference centre Yes/No
Device implantation volumes Numbers/year
Demographic factors
Age Date of birth
Gender Sex at birth
Race Ethnicity per country
Intravenous drug abuse Yes/No
Educational level Level of schooling completed
Baseline clinical factors
Comorbidities Chronic kidney disease Yes/No
Diabetes mellitus Yes/No
Heart failure Yes/No
Valve prosthesis Yes/No
Cancer Yes/No
HIV infection Yes/No
Medications Oral anticoagulants Yes/No
Corticosteroids Yes/No
Immunosuppressant drugs Yes/No
Continued
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Table 14 Continued
Variable group Data field Value domain
Specific risk factors Percutaneous catheters for various indications (infusion,
PM, haemodialysis)
Yes/No
CIED characteristics Type of CIED
Pacemaker DDD, SSI
ICD VR
ICD DR
CRT-P
CRT-D
ICD-subcutaneous
Leadless PM
Pulse generator pocket location Pectoral/abdominal
Lead access Transvenous/epicardial/subcutaneous/hybrid
Date of CIED implantation YYYY-MM-DD or estimated
Total leads number (number)
Abandoned leads Yes/No
Leads on both sides of the chest Yes/No
Prior treatments
Last CIED procedure Initial implantation/generator replacement/lead re-
vision/upgrade
Date of infection diagnosis (time between last CIED proce-
dure and current infection episode)
YYYY-MM-DD or estimated
Abandoned leads None/transvenous/epicardial
Admission related to current infection episode
Date of admission YYYY-MM-DD
Symptoms—fever or hypotension Yes/No
Signs of generator pocket infection Yes/No
Signs of systemic infection Yes/No
Septic shock Yes/No
Diagnostic methods
Blood cultures Microbial pathogens
TE echocardiogram findings CIED-related, RA, or RV mass
Tricuspid vegetation
Left sided vegetation
Duke-criteria diagnosis Definite CIED-related infection
Suspected CIED-related infection
[18F]FDG PET/CT findings CIED-related glycolytic activity
Absence of glycolytic activity
Final diagnosis Early post-implantation incision inflammation
Uncomplicated pocket infection
Complicated pulse generator pocket infection
CIED-lead infection
CIED-associated infective endocarditis
Treatment Antibiotic therapy
Initial date of antibiotic therapy YYYY-MM-DD
Empirical antibiotic therapy Yes/No
Antibiotic target
Dose/route
Directed (blood culture based) antibiotic therapy Yes/No
Antibiotic type
Dose/route
Antibiotic therapy length (before CIED removal) Days
Antibiotic therapy length (after CIED removal) Days
Antibiotic therapy complications Yes/No
Type
Continued
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Table 14 Continued
Variable group Data field Value domain
Treatment CIED removal
Date of pulse generator removal YYYY-MM-DD
Date of leads removal YYYY-MM-DD
Lead extraction procedure Simple traction, locking stylet, simple mechanical
extraction sheath, rotational mechanical extrac-
tion sheath, laser sheath, femoral snare approach,
internal jugular snare approach, other tools, con-
comitant percutaneous aspiration of vegetations,
surgical extraction without CPB, surgical extrac-
tion with CPB
Lead extraction outcomes Complete/incomplete, major/minor complications
Generator pocket tissue culture Yes/No
Main findings
Lead-tip culture Yes/No
Main findings
Wound closure Primary wound closure—drain, delayed closure—
negative pressure wound therapy
Treatment CIED reimplant
Date of re-implantation YYYY-MM-DD
Type of CIED Pacemaker, ICD, CRT
Pulse generator pocket location Pectoral/abdominal
Lead access Transvenous/epicardial/hybrid/leadless pacemaker/
S-ICD
Outcomes
Date of hospital discharge YYYY-MM-DD
Clinical condition at discharge Resolved infection/unresolved infection/death
Need of rehospitalization Yes/No
Date of rehospitalization YYYY-MM-DD
Recurrent infection Yes/No
Death Yes/No
Date of death YYYY-MM-DD
Cause of death Lead extraction complications
CIED infection (sepsis)
CIED dysfunction
Refractory heart failure
Cardiac death—other
Non-cardiac causes
Non-detected cause
Other
CIED, cardiac implantable electronic device; CRT, cardiac resynchronization therapy; ICD, implantable cardiac defibrillator; PM, pacemaker.
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registries both in the scientific and clinical settings. The necessity of
capturing individual parameters will depend upon the purpose of the
study/registry.
Gaps of evidence
(1) The long-term mortality in patients with CIED infection is up
to 2.5 times the mortality rate of non-infected patients. It is
unclear whether it is related to the CIED infection itself, poor
prognostic patient-related factors or inadequate management.
(2) The optimal time for re-intervention (e.g. for lead reposition-
ing) in order to reduce risk for infection is unclear.
(3) The protective role of adhesive antibiotic surgical or other
drapes for preventing infections is unclear.
(4) An optimal risk stratification strategy or risk calculator to mini-
mize risk for CIED infection is lacking.
(5) The role of [18F]FDG PET/CT and scintigraphy with labelled
leucocytes in the diagnosis and follow-up of occult and mani-
fest CIED infections is of growing evidence of clinical utility but
needs clarification.
(6) Duration of postoperative antibiotic therapy following
complete CIED system removal for infectious reasons is
unclear.
(7) The most optimal salvage strategy in severely ill or frail patients
with CIED infections considered too high risk for complete
system removal is unknown.
(8) The appropriate timing of re-implantation after CIED infec-
tions is unclear.
(9) In PM-dependent patients with CIED infection, the best strat-
egy for permanent pacemaker treatment following lead ex-
traction is unclear; an active-fixation lead ipsilaterally
connected to an externalized PM followed by contralateral de-
vice implantation, an epicardial lead placement, or a LPM.
(10) In case of a pocket infection with contralateral abandoned lead
without systemic infection, it is unclear whether the contralat-
eral abandoned lead should be extracted or not.
Summary of emerging messages and
call for scientific evidence
(1) Cardiac implantable electronic device infection rates seem
lower (1.2%) in prospective studies6–10 than in retrospective
registries (3.4%),11,12 which may be related to strengthened
adherence to broad infection-preventative behaviours when
participating in prospective studies. An assessment of the true
infection rates in real-world practice is urgently warranted to
more precisely be able to define the benefit of various struc-
tured preventive programmes, targeting modifiable risk fac-
tors, and developing risk stratification schemes for device
implantation and re-implantations.
(2) Although several guidelines and recommendations have been
published from various medical societies for managing CIED
infections, the EHRA worldwide survey on the clinical practice
in managing CIED infections1 disclosed significant regional dif-
ferences in current practice, incomplete adherence to guide-
line recommendations and a lack of profound knowledge in
CIED infection management, which underline the need for
more widespread and user-friendly international guidelines
and implementation programs.
(3) The timing of an extraction procedure should be without time
delay after diagnosis of CIED infection since if performed
within 3 days after hospitalization it results in significantly
lower in-hospital mortality and shorter hospitalizations. Better
diagnostic tools are warranted.
(4) The most important procedure-related risk factors for device-
related infections are pocket haematoma, long procedure du-
ration, and re-intervention for lead repositioning. Strategies to
prevent these risks should be better defined and undertaken
more vigorously.
(5) Antibacterial envelope reduces CIED infections in patients
with risk factors for device-related infections and is recom-
mended in high-risk patients. Further analysis derived from
‘real world’ practice will provide more information on its effec-
tiveness and performance in less-selected settings. A risk strati-
fication scheme is warranted to optimize its use.
(6) Postoperative antibiotic is generally not recommended.
(7) Needle aspiration and surgical debridement in cases of pocket
infection as an attempt to avoid lead extraction is discouraged.
Better diagnostic tools are warranted.
(8) [18F]FDG PET/CT scanning or radiolabelled WBC scintigraphy
or contrast-enhanced CT are recommended if suspected
CIED-related infective endocarditis, positive blood cultures,
and negative echocardiography.
(9) [18F]FDG PET/CT scanning should be performed in case of S.
aureus bacteraemia in the presence of CIED.
(10) Prudent large national or international non-voluntary user-
friendly quality registries of device implantations and its com-
plications with regular monitoring and national requirements
of minimal annual operators/centre device volumes may be
the ultimate approach to reduce device-related infections.
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